

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 November 2003 (20.11.2003)

PCT


(10) International Publication Number
WO 03/094845 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number: PCT/US03/14222
- (22) International Filing Date: 7 May 2003 (07.05.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/378,497 8 May 2002 (08.05.2002) US
- (71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ZHANG, Minsheng** [US/US]; 31 Scheurman Terrace, Warren, NJ 07059 (US). **HANGELAND, Jon** [US/US]; 234 Louise Drive, Morrisville, PA 19067 (US). **CARINGAL, Yolanda** [US/US]; 307 Fountayne Lane, Lawrenceville, NJ 08648 (US). **FRIENDS, Todd** [US/US]; 12 Chatham Court, Robbinsville, NJ 08691 (US).
- (74) Agents: **O'BRIEN, Maureen** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/094845 A2

(54) Title: PYRIDINE-BASED THYROID RECEPTOR LIGANDS



(57) Abstract: Novel pyridine-based thyroid receptor ligands are provided which have the general formula (I) wherein: X is oxygen (-O-), sulfur (-S-), sulfoxide (-S(O)-), sulfonyl (-SO₂-), CR₈R₈' or NR₈; Y is -NR₈, oxygen (-O-), -CH₂- or sulfur (-S-); Z is a bond or substituted or unsubstituted C₁₋₄ alkyl; and wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a

T₃ regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

PYRIDINE-BASED THYROID RECEPTOR LIGANDS**Cross-Reference to Related Application**

This application claims the benefit of U.S. Provisional Application No. 60/378,497, filed May 8, 2002,
10 which is incorporated herein by reference in its entirety.

Field of the Invention

This invention relates to novel pyridine-based compounds which are thyroid receptor ligands and are
15 preferably selective for the thyroid hormone receptor β . Further, the present invention relates to methods for using such compounds and to pharmaceutical compositions containing such compounds.

20 **Background of the Invention**

While the extensive role of thyroid hormones in regulating metabolism in humans is well recognized, the discovery and development of new specific drugs for
25 improving the treatment of hyperthyroidism and hypothyroidism has been slow. This has also limited the development of thyroid agonists and antagonists for treatment of other important clinical indications, such as hypercholesterolemia, obesity and cardiac arrhythmias.

30 Thyroid hormones affect the metabolism of virtually every cell of the body. At normal levels, these hormones maintain body weight, metabolic rate, body temperature and mood, and influence blood levels of serum low density lipoprotein (LDL). Thus, in hypothyroidism there is weight
35 gain, high levels of LDL cholesterol, and depression. In hyperthyroidism, these hormones lead to weight loss, hypermetabolism, lowering of serum LDL levels, cardiac

5 arrhythmias, heart failure, muscle weakness, bone loss in postmenopausal women, and anxiety.

Thyroid hormones are currently used primarily as replacement therapy for patients with hypothyroidism. Therapy with L-thyroxine returns metabolic functions to
10 normal and can easily be monitored with routine serum measurements of levels of thyroid-stimulating hormone (TSH), thyroxine (3,5,3',5'-tetraiodo-L-thyronine, or T_4) and triiodothyronine (3,5,3'-triiodo-L-thyronine, or T_3). However, replacement therapy, particularly in older
15 individuals, may be restricted by certain detrimental effects from thyroid hormones.

In addition, some effects of thyroid hormones may be therapeutically useful in non-thyroid disorders if adverse effects can be minimized or eliminated. These potentially
20 useful influences include weight reduction, lowering of serum LDL levels, amelioration of depression and stimulation of bone formation. Prior attempts to utilize thyroid hormones pharmacologically to treat these disorders have been limited by manifestations of hyperthyroidism, and in
25 particular by cardiovascular toxicity.

Development of specific and selective thyroid hormone receptor ligands, particularly agonists of the thyroid hormone receptor could lead to specific therapies for these common disorders, while avoiding the cardiovascular and
30 other toxicity of native thyroid hormones. Tissue-selective thyroid hormone agonists may be obtained by selective tissue uptake or extrusion, topical or local delivery, targeting to cells through other ligands attached to the agonist and targeting receptor subtypes. Thyroid hormone receptor
35 agonists that interact selectively with the β -form of the thyroid hormone receptor offers an especially attractive method for avoiding cardio-toxicity.

5 Thyroid hormone receptors (TRs) are, like other
nuclear receptors, single polypeptide chains. The various
receptor forms appear to be products of two different genes
 α and β . Further isoform differences are due to the fact
that differential RNA processing results in at least two
10 isoforms from each gene. The $TR\alpha_1$, $TR\beta_1$ and $TR\beta_2$ isoforms
bind thyroid hormone and act as ligand-regulated
transcription factors. In adults, the $TR\beta_1$ isoform is the
most prevalent form in most tissues, especially in the liver
and muscle. The $TR\alpha_2$ isoform is prevalent in the pituitary
15 and other parts of the central nervous system, does not bind
thyroid hormones, and acts in many contexts as a
transcriptional repressor. The $TR\alpha_1$ isoform is also widely
distributed, although its levels are generally lower than
those of the $TR\beta_1$ isoform. Whereas many mutations in the $TR\beta$
20 gene have been found and lead to the syndrome of generalized
resistance to thyroid hormone, mutations leading to impaired
 $TR\alpha$ function have not been found.


A growing body of data suggests that many or most
effects of thyroid hormones on the heart, and in particular,
25 on the heart rate and rhythm, are mediated through the α -
form of the $TR\alpha_1$ isoform, whereas most actions of the
hormone such as on the liver, muscle and other tissues, are
mediated more through the β -forms of the receptor. Thus, a
 $TR\beta$ -selective agonist might not elicit the cardiac rhythm
30 and rate influences of the hormones, but would elicit many
other actions of the hormones. Applicants believe that the
 α -form of the receptor is primarily associated with heart
rate function for the following reasons:

- 1) tachycardia is very common in the syndrome of
35 generalized resistance to thyroid hormone in which
there are defective $TR\beta$ -forms, and high
circulating levels of T_4 and T_3 ;

- 5 2) there was a tachycardia in the only described patient with a double deletion of the TR β gene (Takeda et al, J. Clin. Endocrinol. & Metab. 1992, Vol. 74, p. 49);
- 3) a double knockout TR α gene (but not β -gene) in mice resulted in a slower mouse heart rate, as compared to control mice; and
- 10 4) western blot analysis of human myocardial TRs show presence of the TR α_1 , TR α_2 and TR β_2 proteins, but not TR β_1 .
- 15 If these indications are correct, then it may be possible that a TR β -selective agonist could be used to mimic a number of thyroid hormone actions, while having a lesser effect on the heart. Such a compound may be used for: (1) replacement therapy in elderly subjects with hypothyroidism
- 20 who are at risk for cardiovascular complications; (2) replacement therapy in elderly subjects with subclinical hypothyroidism who are at risk for cardiovascular complications; (3) obesity; (4) hypercholesterolemia due to elevations of plasma LDL levels; (5) depression; and (6)
- 25 osteoporosis in combination with a bone resorption inhibitor.

Summary of the Invention

- 30 In accordance with the illustrative embodiments and demonstrating features of the present invention, compounds are provided which are thyroid receptor ligands, and have the general formula I



35

5 wherein

X is oxygen (-O-), sulfur (-S-), sulfoxide (-S(O)-), sulfonyl (-SO₂-), CR₈R₈' or NR₈;

Y is oxygen (-O-), -NR₈, -CH₂- or sulfur (-S-);

Z is a bond or substituted or unsubstituted C₁₋₄ alkyl;

10 R₁ is halogen, trifluoromethyl, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted amide, sulfone, sulfonamide, aryloxy or C₃₋₇ cycloalkyl, wherein said aryl, heteroaryl or cycloalkyl ring(s) are attached or
15 fused to the aromatic ring;

R_{1a} is hydrogen, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R₂ and R₃ are each independently hydrogen, halogen,
20 substituted or unsubstituted C₁₋₄ alkyl or substituted or unsubstituted C₃₋₅ cycloalkyl, wherein at least one of R₂ and R₃ being other than hydrogen;

R₄ is hydrogen, halogen, amino, O-R₇, S-R₇ or C₁₋₄ alkyl;

25 R₅ is hydroxyl (-OH), carboxylic acid (-COOH), sulfonic acid (-SO₃H) or phosphonic acid (-PO₃H₂);

R₆ is hydrogen, alkyl, alkanoyl or aroyl (such as acetyl or benzoyl);

R₇ is hydrogen or C₁₋₄ alkyl;

30 R₈ for each occurrence is independently hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, arylalkyl or
35 substituted arylalkyl, alkoxy or hydroxyl; and

R₈' is hydrogen, a bond, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl,

5 heterocyclo or substituted heterocyclo, aryl or substituted aryl, arylalkyl or substituted arylalkyl, alkoxy or hydroxyl, or R₈ and R₈' together form a carbonyl (-CO-).

The definition of formula I above includes all prodrug-esters, stereoisomers and pharmaceutically
10 acceptable salts of formula I.

The compounds of formula I are thyroid hormone receptor ligands and include compounds which are, for example, selective agonists, partial agonists, antagonists or partial antagonists of the thyroid receptor.

15 Preferably, the compounds of formula I possess activity as agonists of the thyroid receptor, preferably selective agonists of the thyroid receptor-beta, and may be used in the treatment of diseases or disorders associated with thyroid receptor activity. In particular, the compounds of
20 formula I may be used in the treatment of diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T₃ regulated gene, such as obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis,
25 hypothyroidism, goiter, thyroid cancer, glaucoma, skin disorders or diseases and congestive heart failure.

The present invention provides for compounds of formula I, pharmaceutical compositions employing such compounds and for methods of using such compounds. In
30 particular, the present invention provides for a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, alone or in combination with a pharmaceutically acceptable carrier.

Further, in accordance with the present invention, a
35 method is provided for preventing, inhibiting or treating the progression or onset of diseases or disorders associated with the thyroid receptor, particularly, the thyroid receptor-beta, such as the diseases or disorders

5 defined above and hereinafter, wherein a therapeutically effective amount of a compound of formula I is administered to a mammalian, i.e., human patient in need of treatment.

The compounds of the invention can be used alone, in combination with other compounds of the present invention,
10 or in combination with one or more other agent(s) active in the therapeutic areas described herein.

In addition, a method is provided for preventing, inhibiting or treating the diseases as defined above and hereinafter, wherein a therapeutically effective amount of
15 a combination of a compound of formula I and another compound of the invention and/or another type of therapeutic agent, is administered to a mammalian patient in need of treatment.

Preferably, compounds of this invention include
20 embodiments of formula I wherein

X is oxygen, sulfur, sulfoxide, sulfonyl, -CH₂- or -NH-;

Y is oxygen or -NH-;

R₁ is halogen, substituted or unsubstituted C₁₋₆ alkyl, C₃₋, cycloalkyl, substituted aryl, aryloxy, substituted
25 amide, sulfone or sulfonamide, wherein R₁ is attached ortho to the R₆O- group;

R₂ and R₃ are each independently iodo, bromo, chloro or fluoro;

30 R₄ is hydrogen, fluoro, chloro, amino, -OCH₃, hydroxyl (-OH) or methyl;

R₅ is carboxylic acid; and

R₆ is hydrogen.

Other preferred embodiments of the invention include
35 compounds of formula I wherein

X is carbonyl, CHR₈ or NR₈;

Y is oxygen or -NH-;

5 R_1 is halogen, substituted or unsubstituted C_{1-6} alkyl, substituted aryl, substituted amide, sulfone, sulfonamide or C_{3-7} cycloalkyl;

R_2 and R_3 are independently bromo, chloro or methyl;


10 R_4 is hydrogen, fluoro, chloro, hydroxyl, amino, methoxy or methyl;

R_5 is a carboxylic acid; and

R_6 is hydrogen.

Further preferred embodiments of the invention include compounds of formula I having the structure:

15



wherein

Y is oxygen or $-NH-$.

20 R_{1a} is hydrogen, methyl or ethyl;

R_2 and R_3 are halogen;

R_4 is hydrogen, halogen, amino, $-OCH_3$ or hydroxyl; and

R_{10} is hydrogen, halogen or substituted or unsubstituted C_{1-4} alkyl.

25

Detailed Description of the Invention

The following abbreviations have the indicated meanings:

30

Ar = aryl

Bn = benzyl

DMF = N,N-dimethylformamide

DMSO = dimethyl sulfoxide

- 5 Et = ethyl
EtOAc = ethyl acetate
g = gram(s)
h or hr = hour(s)
Me = methyl
- 10 M+H = parent plus a proton
min = minute(s)
mL = milliliter
mg = milligram(s)
mol = moles
- 15 mmol = millimole(s)
M = molar
Ph = phenyl
RT = room temperature
HPLC = high performance liquid chromatography
- 20 NMR = nuclear magnetic resonance
THF = tetrahydrofuran
TFA = trifluoroacetic acid
μL = microliter

- 25 The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances.

- The term "thyroid receptor ligand" as used herein is intended to cover any moiety which binds to a thyroid
- 30 receptor. The ligand may act as an agonist, an antagonist, a partial agonist or a partial antagonist. Another term for "thyroid receptor ligand" is "thyromimetic".

- Unless otherwise indicated, the term "alkyl" as employed herein alone or as part of another group includes
- 35 both straight and branched chain hydrocarbons, containing 1 to 12 carbons in the normal chain, preferably 1 to 4 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, or isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-

5 dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl. "Substituted alkyl" includes an alkyl group optionally substituted with one or more functional groups which are commonly attached to such chains, such as, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, hydroxy, cyano, nitro, amino, halo, carboxyl or alkyl ester thereof and/or carboxamide, substituted or unsubstituted.

Unless otherwise indicated, the term "alkoxy" refers to alkyl-O-. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.

The term "aryl" or "Ar" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl). "Substituted aryl" includes an aryl group optionally substituted through available carbon atoms with one or more groups selected from hydrogen, halo, substituted or unsubstituted alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, hydroxy, amino, nitro, cyano and/or any of the alkyl substituents set out herein.

The term "alkanoyl" refers to alkyl-C(O)-.

The term "aroyl" refers to aryl-C(O)-.

Unless otherwise indicated, the term "aryloxy" as employed herein, alone or as part of another group, denotes -OR- wherein R is aryl as defined herein.

The term "heteroaryl" means a 5- or 6-membered aromatic heterocyclic ring which contains one or more heteroatoms selected from nitrogen, sulfur, oxygen and/or a SO or SO₂ group. Such rings may be fused to another aryl or heteroaryl ring and include possible N-oxides. "Substituted heteroaryl" includes a heteroaryl group optionally

5 substituted with one or more substituents, such as those described for substituted alkyl and/or substituted aryl.

The term "amino" as used herein refers to $-NR_A R_B$ where R_A and R_B are independently hydrogen, or R_A and/or R_B may optionally be a substituent, such as aryl, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, cyano, nitro, carboxyl, halo, alkylthio, heteroaryl, heterocycle, heterocycle(aryl) carboalkyl and the like.

The term "substituted amide" as used herein refers to an amide linkage: $-C(O)NR$ where R is hydrogen or may optionally be a substituent, such as aryl, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, cyano, nitro, amino, carboxyl, halo, alkylthio, heteroaryl, heterocycle carboalkyl and the like.

The term "sulfonamide" as used herein refers to a sulfonamide linkage: $-SO_2NRR'$ where R and R' are independently hydrogen, or one or both of R and R' may optionally be substituents, such as any of the substituents described in the definition of substituted alkyl or substituted amino.

The term "sulfone" as used herein refers to a sulfone linkage: $-SO_2R$ where R is hydrogen or may optionally be a substituent, such as aryl, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, cyano, nitro, amino, carboxyl, halo, alkylthio, heteroaryl, heterocycle carboalkyl and the like.

The term "heterocycle" or "heterocyclo" as used herein, represents a 5- to 7-membered monocyclic ring system which may be saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from N, O or S. Exemplary monocyclic heterocyclo groups include 2- and 3-thienyl, 2- and 3-furyl, 2-, 3-, and 4-pyridyl and imidazolyl. The term heterocycle or heterocyclic ring also includes bicyclic rings wherein the five- or six-membered ring containing oxygen and/or sulfur

5 and/or nitrogen atoms as defined above is fused to a
benzene ring and the bicyclic ring is attached by way of an
available atom. Exemplary bicyclic heterocycle groups
include 4-, 5-, 6- or 7-indolyl, 4-, 5-, 6-, or 7-
isoindolyl, 5-,6-,7- or 8-quinolinyl, 5-,
10 6-, 7- or 8-isoquinolinyl and 4-, 5-, 6- or 7-
benzothiazoyl. "Substituted heterocyclo" includes a
heterocyclo group optionally substituted with one or more
substituents, such as those described for substituted alkyl
and/or substituted aryl.

15 Unless otherwise indicated, the term "alkenyl" as
used herein refers to straight or branched chain radicals
of 2 to 20 carbons, preferably 2 to 12 carbons, and more
preferably 2 to 8 carbons in the normal chain, which
include one or more double bonds in the normal chain, such
20 as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-
pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-
heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-
dodecenyl, 4,8,12-tetradecatienyl, and the like.

"Substituted alkenyl" includes an alkenyl group optionally
25 substituted with one or more substituents, such as those
described for substituted alkyl and/or substituted aryl.

The term "arylalkyl" refers to alkyl groups as
described above having an aryl substituent. Representative
examples of arylalkyl include, but are not limited to,
30 benzyl, 2-phenylethyl, 3-phenylpropyl and the like.
"Substituted arylalkyl" includes an arylalkyl group
optionally substituted with one or more substituents, such
as those described for substituted alkyl and/or substituted
aryl.

35 The term "cycloalkyl" or "cycloalkenyl" as used
herein includes saturated or partially saturated
(containing one or more double bonds) cyclic hydrocarbon
groups containing 3 to 7 carbon atoms, such as cyclopropyl,

5 cyclobutyl, cyclopentyl, cyclohexyl. "Substituted cycloalkyl" or "substituted cycloalkenyl" include a cycloalkyl or cycloalkenyl group optionally substituted with one or more substituents, such as those described for substituted alkyl and/or substituted aryl.

10 The term "halogen" or "halo" as used herein alone or as part of another group refers to chlorine, bromine, fluorine and iodine, with chlorine or bromine being preferred.

The $(CH_2)_n$ group is an alkyl group that includes 0 to 15 4 carbons in the normal chain which may include 1, 2, or 3 alkyl substituents.

The term "carbonyl", as used herein, refers to a $-C(O)-$ group.

The compounds of formula I can be present as salts, 20 which are also within the scope of this invention. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred. If the compounds of formula I have, for example, at least one basic center, they can form acid addition salts. These are 25 formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, 30 for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, 35 (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C_1-C_4) alkyl or arylsulfonic acids which are unsubstituted or substituted, for example by halogen, for

5 example methyl- or p-toluene- sulfonic acid. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds of formula I having at least one acid group (for example COOH) can also form salts with bases. Suitable salts with bases
10 are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono, di or tri-lower alkylamine, for example ethyl,
15 tertbutyl, diethyl, diisopropyl, triethyl, tributyl or dimethyl-propylamine, or a mono, di or trihydroxy lower alkylamine, for example mono, di or triethanolamine. Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which
20 can be employed, for example, for the isolation or purification of free compounds of formula I or their pharmaceutically acceptable salts, are also included.

Preferred salts of the compounds of formula I which contain a basic group include monohydrochloride,
25 hydrogensulfate, methanesulfonate, phosphate or nitrate.

Preferred salts of the compounds of formula I which contain an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amines.

30 The compounds of formula I may also have prodrug forms. Any compound that will be converted in vivo to provide the bioactive agent (i.e., the compound of formula I) is a prodrug within the scope and spirit of the invention.

35 Various forms of prodrugs are well known in the art. A comprehensive description of prodrugs and prodrug derivatives may be found in:

- 5 a.) *The Practice of Medicinal Chemistry*, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996);
 b.) *Design of Prodrugs*, edited by H. Bundgaard, (Elsevier, 1985); and
 c.) *A Textbook of Drug Design and Development*, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch 5,
10 pgs 113 - 191 (Harwood Academic Publishers, 1991).


Said references are incorporated herein by reference.

Embodiments of prodrugs suitable for use in the
15 present invention include lower alkyl esters, such as ethyl ester, or acyloxyalkyl esters such as pivaloyloxymethyl (POM).

An administration of a therapeutic agent of the invention includes administration of a therapeutically
20 effective amount of the agent of the invention. The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent to treat or prevent a condition treatable by administration of a composition of the invention. That amount is the amount sufficient to
25 exhibit a detectable therapeutic or preventative or ameliorative effect. The effect may include, for example, treatment or prevention of the conditions listed herein. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the
30 condition being treated, recommendations of the treating physician, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance.

The compounds of formula I of the invention can be
35 prepared as shown in the following reaction schemes and description thereof, as well as by relevant published literature procedures that may be used by one skilled in the art. Exemplary reagents and procedures for these

5 reactions appear hereinafter and in the working Examples. Protection and deprotection in the Schemes below may be carried out by procedures generally known in the art. For example, see T. W. Greene & P. G. M. Wuts, "Protecting Groups in Organic Synthesis", 3rd Edition, (Wiley, 1999),
 10 incorporated herein by reference.

SCHEME 1a

15


Scheme 1 depicts a general synthetic approach to compounds of formula I wherein X = O, S or NR₈, which utilizes the displacement reaction of an appropriately substituted phenol, thiophenol or aniline 1 such as 3-isopropyl-4-methoxyphenol or 4-methoxynaphthol with a
 20 pentasubstituted pyridine 2 such as 3,5-dichloro-2,4,6-trifluoropyridine or pentafluoro pyridine to provide intermediate 3. In structure 1 and all other applicable structures contained in further schemes described below, the term "PG" refers to a protecting group appropriate for
 25 the functional group indicated (in this instance, for a phenolic oxygen). Subsequent displacement of the 2-fluoro and 6-fluoro substituents on the pyridine 3 with nucleophiles 4 and reactant HR₄ sequentially provide

5 intermediates 5 and 6 respectively. Examples of suitable
nucleophiles 4 include, but are not limited to, glycine
methyl ester and methyl glycolate. Examples of reactant HR_4
include, but are not limited to, alkylthiol, sodium
alkoxide, alkylamine, or benzylamine. Compounds of formula
10 I wherein X is sulfoxide or sulfonyl can be derived from
intermediates 5 or 6 when X is S, via oxidation with an
oxidating agent, for example mCPBA. Further protecting
group and functional group manipulation of intermediates 5
or 6 will provide the compounds of formula I where X is O,
15 S, NR_8 , sulfoxide and sulfonyl.

For example, where intermediate 1 is 3-isopropyl-4-
methoxy phenol (X is oxygen) and intermediate 2 is 3, 5-
dichloro-2, 4, 6-trifluoro pyridine (R_2 and R_3 are
chlorine), the resulting intermediate 3 would be the
20 corresponding diaryl ether where $X = O$ and $R_2 = R_3 = Cl$.
The 2-fluoro substituent of this intermediate can be
readily displaced with nucleophile 4 where Y is O, NR_8 , CH_2
or sulfur, such as an amine or alkoxide, to form
intermediate 5. The 6-fluoro substituent of the resulting
25 amino or alkoxy pyridine 5 can then be further displaced
with a third nucleophile, such as ethylthiol in presence of
potassium carbonate to provide the intermediate 6.
Deprotection or Raney-Nickel desulfurization of 5 and/or 6
would provide the desired compounds of formula I wherein R_4
30 = F or H.


Poly-substituted prime rings may be prepared by using
commercially available polysubstituted phenols as
illustrated below in Scheme 1b where X represents a halogen.

35

5 **SCHEME 1b**

Alternatively, poly-substitutions can be achieved by
 10 halogenation of intermediate Ia or its acyl derivative,
 intermediate IIa, followed by hydrolysis. Conversion of the
 halogens (X) to an alkyl, aryl or heteroaryl may be achieved
 by subsequent Steele or Suzuki coupling reactions with
 tetraalkyltin or aryl boronic acid reagents.

5

SCHEMES 2a & 2b**SCHEME 2a**


10

Scheme 2 depicts another general synthetic approach to produce the compounds of formula I wherein $\text{X} = \text{O}$ in which the position adjacent (ortho) to $\text{O}-\text{PG}$ ($\text{R}_1 = \text{H}$) can be functionalized via sulfonation/sulfonylation, bromination or formylation to provide intermediate **7**, **8** and **9**. Conversion of CHO to COOH and to N -substituted amide may be carried out

5 by methods well known in the art, such as oxidation of the
 formyl group of intermediate **9** to form intermediate **10**.
 Carbodiimide promoted coupling of an amine with the
 resulting carboxylic acid of intermediate **10** provides
 intermediate **11** wherein R_1 = an amide. Subsequent
 10 displacement of the 2-fluoro substituent of **11** with an amine
 or alkoxide **4**, where $Y = NH$ or O , as described in the
 description of Scheme 1, provides intermediate **5**.
 Displacement of the 2-fluoro substituent of **8** with **4**
 provides **12**. Subsequent Suzuki coupling of the aryl bromide
 15 **12** with substituted phenylboronic acid provides **5** wherein R_1
 = Aryl.


Chloronation of the aryl sulfonic acid **7** wherein
 $R^1 = OH$, followed by addition of an amine or aniline
 provides the aryl sulfonamide intermediate **13**. Displacement
 20 of the 2 fluoro substituent of **13** or **7** wherein $R^1 = Ar$, with
4 provides **5** wherein R_1 = sulfonamide or sulfone.

SCHEME 2b



Scheme 2b depicts Baeyer-Villiger oxidation of the
 intermediate **9** followed by hydrolysis provides **14**.
 Treatment of **14** with aryl boronic acids under Evan's
 30 conditions (see D. A. Evans et al., Tetrahedron Lett., 39,

2937-2940, 1998) provides intermediate **15**. Subsequent displacement of the 2-fluoro substituent of **15** with **4** provides **5** wherein R_1 = aryloxy. Further protecting group and functional group manipulation of the intermediate **5** will provide the desired compounds of formula I where X is oxygen.

SCHEME 3

15

5 Alternatively, compounds of formula I in which X is $\text{CR}_2\text{R}_2'$ or CO may be prepared as shown in Scheme 3. Conversion of **2** to **18** may be achieved via displacement of the 4-fluoro substituent of **2** with **16** followed by displacement of the 2-fluoro substituent of **17** with
10 nucleophile **4**. Oxidation of **18** provides **19**. Deprotection and functional group manipulation of **19** provides compounds of formula I wherein X is CO. Alternatively, reductive deoxygenation of **19** affords **20**. Deprotection of **20** provides intermediate **22**. Alternatively, Wittig olefination of **19**
15 provides intermediate **21**. Hydrogenation, deprotection and functional group manipulation of **21** provides intermediate **22**. Deprotection and functional group manipulation of **22** provides compounds of formula I where X is $\text{CR}_2\text{R}_2'$.

20 Further methods applicable to the synthesis of compounds of formula I in which X = O and R_2 and R_2' are independently varied as hydrogen, halogen and alkyl are described in Li et al., WO 99/00353.

25 All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of the carbon atoms including any one of the R substituents. Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof.
30 The processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods. For example, chromatographic or fractional crystallization.

35

5 UTILITIES & COMBINATIONS

A. UTILITIES

The compounds of the present invention are thyroid
10 receptor ligands, and include compounds which are, for
example, selective agonists, partial agonists, antagonists
or partial antagonists of the thyroid receptor. Preferably
compounds of the present invention possess activity as
agonists of the thyroid receptor, preferably selective
15 agonists of the thyroid receptor-beta, and may be used in
the treatment of diseases or disorders associated with
thyroid receptor activity. In particular, compounds of the
present invention may be used in the treatment of diseases
or disorders associated with metabolism dysfunction or
20 which are dependent upon the expression of a T₃ regulated
gene.

Accordingly, the compounds of the present invention
can be administered to mammals, preferably humans, for the
25 treatment of a variety of conditions and disorders,
including, but not limited to hypothyroidism; subclinical
hyperthyroidism; non-toxic goiter; atherosclerosis; thyroid
hormone replacement therapy (e.g., in the elderly);
malignant tumor cells containing the thyroid receptor;
30 papillary or follicular cancer; maintenance of muscle
strength and function (e.g., in the elderly); reversal or
prevention of frailty or age-related functional decline
("ARFD") in the elderly (e.g., sarcopenia); treatment of
catabolic side effects of glucocorticoids; prevention
35 and/or treatment of reduced bone mass, density or growth
(e.g., osteoporosis and osteopenia); treatment of chronic
fatigue syndrome (CFS); accelerating healing of complicated
fractures, e.g. distraction osteogenesis; in joint

5 replacement; eating disorders (e.g., anorexia); treatment
of obesity and growth retardation associated with obesity;
treatment of depression, nervousness, irritability and
stress; treatment of reduced mental energy and low self-
esteem (e.g., motivation/assertiveness); improvement of
10 cognitive function (e.g., the treatment of dementia,
including Alzheimer's disease and short term memory loss);
treatment of catabolism in connection with pulmonary
dysfunction and ventilator dependency; treatment of cardiac
dysfunction (e.g., associated with valvular disease,
15 myocardial infarction, cardiac hypertrophy or congestive
heart failure); lowering blood pressure; protection against
ventricular dysfunction or prevention of reperfusion
events; treatment of hyperinsulinemia; stimulation of
osteoblasts, bone remodeling and cartilage growth;
20 regulation of food intake; treatment of insulin resistance,
including NIDDM, in mammals (e.g., humans); treatment of
insulin resistance in the heart; treatment of congestive
heart failure; treatment of musculoskeletal impairment
(e.g., in the elderly); improvement of the overall
25 pulmonary function; skin disorders or diseases, such as
glucocorticoid induced dermal atrophy, including
restoration of dermal atrophy induced by topical
glucocorticoids, and the prevention of dermal atrophy
induced by topical glucocorticoids (such as the
30 simultaneous treatment with topical glucocorticoid or a
pharmacological product including both glucocorticoid and a
compound of the invention), the restoration/prevention of
dermal atrophy induced by systemic treatment with
glucocorticoids, restoration/prevention of atrophy in the
35 respiratory system induced by local treatment with
glucocorticoids, UV-induced dermal atrophy, dermal atrophy
induced by aging (wrinkles, etc.), wound healing, keloids,
stria, cellulite, roughened skin, actinic skin damage,

5 lichen planus, ichthyosis, acne, psoriasis, Dernier's disease, eczema, atopic dermatitis, chloracne, pityriasis and skin scarring.

The term treatment is also intended to include prophylactic treatment.

10

In addition, the conditions, diseases, and maladies collectively referenced to as "Syndrome X" or Metabolic Syndrome as detailed in Johannsson *J. Clin. Endocrinol. Metab.*, 82, 727-34 (1997), may be treated employing the
15 compounds of the invention.

B. COMBINATIONS

The present invention includes within its scope
20 pharmaceutical compositions comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds of formula I, alone or in combination with a pharmaceutical carrier or diluent. Optionally, compounds of the present invention can be used alone, in
25 combination with other compounds of the invention, or in combination with one or more other therapeutic agent(s), e.g., an antidiabetic agent or other pharmaceutically active material.

The compounds of the present invention may be employed
30 in combination with other modulators and/or ligands of the thyroid receptor or other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents; anti-osteoporosis agents; anti-obesity agents; growth promoting agents (including
35 growth hormone secretagogues); anti-inflammatory agents; anti-anxiety agents; anti-depressants; anti-hypertensive agents; cardiac glycosides; cholesterol/lipid lowering agents; appetite suppressants; bone resorption inhibitors;

5 thyroid mimetics (including other thyroid receptor agonists); anabolic agents; and anti-tumor agents.

Examples of suitable anti-diabetic agents for use in combination with the compounds of the present invention include biguanides (e.g., metformin or phenformin),
10 glucosidase inhibitors (e.g., acarbose or miglitol), insulins (including insulin secretagogues or insulin sensitizers), meglitinides (e.g., repaglinide), sulfonylureas (e.g., glimepiride, glyburide, gliclazide, chlorpropamide and glipizide), biguanide/glyburide
15 combinations (e.g., Glucovance®), thiazolidinediones (e.g., troglitazone, rosiglitazone and pioglitazone), PPAR-alpha agonists, PPAR-gamma agonists, PPAR alpha/gamma dual agonists, SGLT2 inhibitors, glycogen phosphorylase inhibitors, inhibitors of fatty acid binding protein (aP2),
20 glucagon-like peptide-1 (GLP-1), and dipeptidyl peptidase IV (DP4) inhibitors.

Examples of suitable anti-osteoporosis agents for use in combination with the compounds of the present invention include alendronate, risedronate, PTH, PTH fragment,
25 raloxifene, calcitonin, RANK ligand antagonists, calcium sensing receptor antagonists, TRAP inhibitors, selective estrogen receptor modulators (SERM) and AP-1 inhibitors.

Examples of suitable anti-obesity agents for use in combination with the compounds of the present invention
30 include aP2 inhibitors, PPAR gamma antagonists, PPAR delta agonists, beta 3 adrenergic agonists, such as AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and
35 5,488,064, a lipase inhibitor, such as orlistat or ATL-962 (Alizyme), a serotonin (and dopamine) reuptake inhibitor, such as sibutramine, topiramate (Johnson & Johnson) or axokine (Regeneron), other thyroid receptor beta drugs,

5 such as a thyroid receptor ligand as disclosed in WO 97/21993 (U. Cal SF), WO 99/00353 (KaroBio) and GB98/284425 (KaroBio), and/or an anorectic agent, such as dexamphetamine, phentermine, phenylpropanolamine or mazindol.

10 The compounds of the present invention may be combined with growth promoting agents, such as, but not limited to, TRH, diethylstilbesterol, theophylline, enkephalins, E series prostaglandins, compounds disclosed in U.S. Patent No. 3,239,345, e.g., zeranol, and compounds
15 disclosed in U.S. Patent No. 4,036,979, e.g., sulbenox or peptides disclosed in U.S. Patent No. 4,411,890.

The compounds of the invention may also be used in combination with growth hormone secretagogues such as GHRP-6, GHRP-1 (as described in U.S. Patent No. 4,411,890 and
20 publications WO 89/07110 and WO 89/07111), GHRP-2 (as described in WO 93/04081), NN703 (Novo Nordisk), LY444711 (Lilly), MK-677 (Merck), CP424391 (Pfizer) and B-HT920, or with growth hormone releasing factor and its analogs or growth hormone and its analogs or somatomedins including
25 IGF-1 and IGF-2, or with alpha-adrenergic agonists, such as clonidine or serotonin 5-HT₂ agonists, such as sumatriptan, or agents which inhibit somatostatin or its release, such as physostigmine and pyridostigmine. A still further use of the disclosed compounds of the invention is in
30 combination with parathyroid hormone, PTH(1-34) or bisphosphonates, such as MK-217 (alendronate).

A still further use of the compounds of the invention is in combination with estrogen, testosterone, a selective estrogen receptor modulator, such as tamoxifen or
35 raloxifene, or other androgen receptor modulators, such as those disclosed in Edwards, J. P. et al., *Bio. Med. Chem. Let.*, 9, 1003-1008 (1999) and Hamann, L. G. et al., *J. Med. Chem.*, 42, 210-212 (1999).

5 A further use of the compounds of this invention is in combination with steriodal or non-steroidal progesterone receptor agonists ("PRA"), such as levonorgestrel, medroxyprogesterone acetate (MPA).

10 Examples of suitable anti-inflammatory agents for use in combination with the compounds of the present invention include prednisone, dexamethasone, Enbrel®, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, aspirin, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®), CTLA4-Ig
15 agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®), integrin antagonists, alpha-4 beta-7 integrin antagonists, cell adhesion inhibitors, interferon gamma antagonists, ICAM-1, tumor necrosis factor (TNF) antagonists (e.g., infliximab, OR1384), prostaglandin synthesis inhibitors, budesonide,
20 clofazimine, CNI-1493, CD4 antagonists (e.g., priliximab), p38 mitogen-activated protein kinase inhibitors, protein tyrosine kinase (PTK) inhibitors, IKK inhibitors, and therapies for the treatment of irritable bowel syndrome
25 (e.g., Zelmac® and Maxi-K® openers such as those disclosed in U.S. Patent No. 6,184,231 B1).

 Example of suitable anti-anxiety agents for use in combination with the compounds of the present invention include diazepam, lorazepam, buspirone, oxazepam, and
30 hydroxyzine pamoate.

 Examples of suitable anti-depressants for use in combination with the compounds of the present invention include citalopram, fluoxetine, nefazodone, sertraline, and paroxetine.

35 For the treatment of skin disorders or diseases as described above, the compounds of the present invention may be used alone or optionally in combination with a retinoid, such as tretinoin, or a vitamin D analog.

5 Examples of suitable anti-hypertensive agents for use
in combination with the compounds of the present invention
include beta adrenergic blockers, calcium channel blockers
(L-type and T-type; e.g. diltiazem, verapamil, nifedipine,
amlodipine and mybefradil), diuretics (e.g.,
10 chlorothiazide, hydrochlorothiazide, flumethiazide,
hydroflumethiazide, bendroflumethiazide,
methylchlorothiazide, trichloromethiazide, polythiazide,
benzthiazide, ethacrynic acid, tricyclic, chlorthalidone,
furosemide, bumetanide, triamterene,
15 amiloride, spironolactone), renin inhibitors, ACE
inhibitors (e.g., captopril, zofenopril, fosinopril,
enalapril, ceranopril, cilazapril, delapril, pentopril,
quinapril, ramipril, lisinopril), AT-1 receptor antagonists
(e.g., losartan, irbesartan, valsartan), ET receptor
20 antagonists (e.g., sitaxsentan, atrisentan and compounds
disclosed in U.S. Patent Nos. 5,612,359 and 6,043,265),
Dual ET/AII antagonist (e.g., compounds disclosed in WO
00/01389), neutral endopeptidase (NEP) inhibitors,
vasopeptidase inhibitors (dual NEP-ACE inhibitors) (e.g.,
25 omapatrilat and gemopatrilat), and nitrates.

Examples of suitable cardiac glycosides for use in
combination with the compounds of the present invention
include digitalis and ouabain.

Examples of suitable cholesterol/lipid lowering agents
30 for use in combination with the compounds of the present
invention include HMG-CoA reductase inhibitors, squalene
synthetase inhibitors, fibrates, bile acid sequestrants,
ACAT inhibitors, MTP inhibitors, lipooxygenase inhibitors,
an ileal Na⁺/bile acid cotransporter inhibitor, cholesterol
35 absorption inhibitors, and cholesterol ester transfer
protein inhibitors (e.g., CP-529414).


MTP inhibitors which may be employed herein in
combination with one or more compounds of formula I include

5 MTP inhibitors as disclosed in U.S. Patent No. 5,595,872, U.S. Patent No. 5,739,135, U.S. Patent No. 5,712,279, U.S. Patent No. 5,760,246, U.S. Patent No. 5,827,875, U.S. Patent No. 5,885,983 and U.S. Patent No. 5,962,440 all incorporated herein by reference.

10 A preferred MTP inhibitor is

9-[4-[4-[[2-(2,2,2-Trifluoroethoxy)benzoyl]amino]-1-piperidinyl] butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide

15



The HMG CoA reductase inhibitors which may be employed in combination with one or more compounds of formula I include mevastatin and related compounds as disclosed in U.S. Patent No. 3,983,140, lovastatin (mevinolin) and related compounds as disclosed in U.S. Patent No. 4,231,938, pravastatin and related compounds such as disclosed in U.S. Patent No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Patent Nos. 4,448,784 and 4,450,171. Further HMG CoA reductase inhibitors which may be employed herein include fluvastatin, disclosed in U.S. Patent No. 5,354,772, cerivastatin disclosed in U.S. Patent Nos. 5,006,530 and 5,177,080, atorvastatin disclosed in U.S. Patent Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104, pyrazole

5 analogs of mevalonolactone derivatives as disclosed in U.S. Patent No. 4,613,610, indene analogs of mevalonolactone derivatives, as disclosed in PCT application WO 86/03488, 6-[2-(substituted-pyrrol-1-yl)-alkyl]pyran-2-ones and derivatives thereof, as disclosed in U.S. Patent No.
10 4,647,576, Searle's SC-45355 (a 3-substituted pentanedioic acid derivative) dichloroacetate, imidazole analogs of mevalonolactone, as disclosed in PCT application WO 86/07054, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives, as disclosed in French Patent No. 2,596,393,
15 2,3-disubstituted pyrrole, furan and thiophene derivatives, as disclosed in European Patent Application No. 0221025, naphthyl analogs of mevalonolactone, as disclosed in U.S. Patent No. 4,686,237, octahydronaphthalenes, such as disclosed in U.S. Patent No. 4,499,289, keto analogs of
20 mevinolin (lovastatin), as disclosed in European Patent Application No.0,142,146 A2, as well as other known HMG CoA reductase inhibitors.

The squalene synthetase inhibitors which may be used in combination with the compounds of the present invention
25 include, but are not limited to, α -phosphono-sulfonates disclosed in U.S. Patent No. 5,712,396, those disclosed by Biller et al, J. Med. Chem., 1988, Vol. 31, No. 10, pp 1869-1871, including isoprenoid (phosphinylmethyl)phosphonates, terpenoid pyrophosphates
30 disclosed by P. Ortiz de Montellano et al, J. Med. Chem., 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc., 1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R.W. et al,
35 J.A.C.S., 1987, 109, 5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, as well as other squalene synthetase

5 inhibitors as disclosed in U.S. Patent No. 4,871,721 and
4,924,024 and in Biller, S.A., Neuenschwander, K.,
Ponpipom, M.M., and Poulter, C.D., Current Pharmaceutical
Design, 2, 1-40 (1996).

Bile acid sequestrants which may be used in
10 combination with the compounds of the present invention
include cholestyramine, colestipol and DEAE-Sephadex
(Secholex®, Policexide®), as well as lipostabil (Rhone-
Poulenc), Eisai E-5050 (an N-substituted ethanolamine
derivative), imanixil (HOE-402), tetrahydrolipstatin (THL),
15 istigmastanylphosphorylcholine (SPC, Roche),
aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814
(azulene derivative), melinamide (Sumitomo), Sandoz 58-035,
American Cyanamid CL-277,082 and CL-283,546 (disubstituted
urea derivatives), nicotinic acid, acipimox, acifran,
20 neomycin, p-aminosalicylic acid, aspirin,
poly(diallylmethylamine) derivatives such as disclosed in
U.S. Patent No. 4,759,923, quaternary amine
poly(diallyldimethylammonium chloride) and ionenes such as
disclosed in U.S. Patent No. 4,027,009, and other known
25 serum cholesterol lowering agents.

ACAT inhibitors suitable for use in combination with
compounds of the invention include ACAT inhibitors as
described in, Drugs of the Future 24, 9-15 (1999),
(Avasimibe); "The ACAT inhibitor, Cl-1011 is effective in
30 the prevention and regression of aortic fatty streak area
in hamsters", Nicolosi et al, Atherosclerosis (Shannon,
Irel). (1998), 137(1), 77-85; "The pharmacological profile
of FCE 27677: a novel ACAT inhibitor with potent
hypolipidemic activity mediated by selective suppression of
35 the hepatic secretion of ApoB100-containing lipoprotein",
Ghiselli, Giancarlo, Cardiovasc. Drug Rev. (1998), 16(1),
16-30; "RP 73163: a bioavailable alkylsulfanyl-
diphenylimidazole ACAT inhibitor", Smith, C., et al,

- 5 Bioorg. Med. Chem. Lett. (1996), 6(1), 47-50; "ACAT
inhibitors: physiologic mechanisms for hypolipidemic and
anti-atherosclerotic activities in experimental animals",
Krause et al, Editor(s): Ruffolo, Robert R., Jr.;
Hollinger, Mannfred A., Inflammation: Mediators Pathways
10 (1995), 173-98, Publisher: CRC, Boca Raton, Fla.; "ACAT
inhibitors: potential anti-atherosclerotic agents",
Sliskovic et al, Curr. Med. Chem. (1994), 1(3), 204-25;
"Inhibitors of acyl-CoA:cholesterol O-acyl transferase
(ACAT) as hypocholesterolemic agents. 6. The first water-
15 soluble ACAT inhibitor with lipid-regulating activity.
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT).
7. Development of a series of substituted N-phenyl-N'-[(1-
phenylcyclopentyl)methyl]ureas with enhanced
hypocholesterolemic activity", Stout et al, Chemtracts:
20 Org. Chem. (1995), 8(6), 359-62.

Examples of suitable cholesterol absorption inhibitor
for use in combination with the compounds of the invention
include SCH48461 (Schering-Plough), as well as those
disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med.
25 Chem. 41, 973 (1998).

Examples of suitable ileal Na⁺/bile acid cotransporter
inhibitors for use in combination with the compounds of the
invention include compounds as disclosed in Drugs of the
Future, 24, 425-430 (1999).

30 Examples of suitable thyroid mimetics for use in
combination with the compounds of the present invention
include thyrotropin, polythyroid, KB-130015, and
dronedarone.

Examples of suitable anabolic agents for use in
35 combination with the compounds of the present invention
include testosterone, TRH diethylstilbesterol, estrogens, β -
agonists, theophylline, anabolic steroids,
dehydroepiandrosterone, enkephalins, E-series

5 prostagladins, retinoic acid and compounds as disclosed in U.S. Pat. No. 3,239,345, e.g., Zeranol®; U.S. Patent No. 4,036,979, e.g., Sulbenox® or peptides as disclosed in U.S. Pat. No. 4,411,890.

The aforementioned patents and patent applications are
10 incorporated herein by reference.

The above other therapeutic agents, when employed in combination with the compounds of the present invention, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined
15 by one of ordinary skill in the art.

Where the compounds of the invention are utilized in combination with one or more other therapeutic agent(s), either concurrently or sequentially, the following combination ratios and dosage ranges are preferred:

20 When combined with a hypolypidemic agent, an antidepressant, a bone resorption inhibitor and/or an appetite suppressant, the compounds of formula I may be employed in a weight ratio to the additional agent within the range from about 500:1 to about 0.005:1, preferably
25 from about 300:1 to about 0.01:1.

Where the antidiabetic agent is a biguanide, the compounds of formula I may be employed in a weight ratio to biguanide within the range from about 0.01:1 to about
30 100:1, preferably from about 0.5:1 to about 2:1.

The compounds of formula I may be employed in a weight ratio to a glucosidase inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to about 50:1.

35 The compounds of formula I may be employed in a weight ratio to a sulfonylurea in the range from about 0.01:1 to about 100:1, preferably from about 0.2:1 to about 10:1.

5 The compounds of formula I may be employed in a weight ratio to a thiazolidinedione in an amount within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to about 5:1.

 The thiazolidinedione may be employed in amounts
10 within the range from about 0.01 to about 2000 mg/day, which may optionally be administered in single or divided doses of one to four times per day.

 Further, where the sulfonylurea and thiazolidinedione are to be administered orally in an amount of less than
15 about 150 mg, these additional agents may be incorporated into a combined single tablet with a therapeutically effective amount of the compounds of formula I.

 Metformin, or salt thereof, may be employed with the compounds of formula I in amounts within the range from
20 about 500 to about 2000 mg per day, which may be administered in single or divided doses one to four times daily.

 The compounds of formula I may be employed in a weight ratio to a PPAR-alpha agonist, a PPAR-gamma agonist,
25 a PPAR-alpha/gamma dual agonist, an SGLT2 inhibitor and/or an α 2 inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to about 5:1.

 An MTP inhibitor may be administered orally with the compounds of formula I in an amount within the range of
30 from about 0.01 mg/kg to about 100 mg/kg and preferably from about 0.1 mg/kg to about 75 mg/kg, one to four times daily.

 A preferred oral dosage form, such as tablets or capsules, may contain the MTP inhibitor in an amount of
35 from about 1 to about 500 mg, preferably from about 2 to about 400 mg, and more preferably from about 5 to about 250 mg, administered on a regimen of one to four times daily.

5 For parenteral administration, the MTP inhibitor may be employed in an amount within the range of from about 0.005 mg/kg to about 10 mg/kg and preferably from about 0.005 mg/kg to about 8 mg/kg, administered on a regimen of one to four times daily.

10 A HMG CoA reductase inhibitor may be administered orally with the compounds of formula I within the range of from about 1 to 2000 mg, and preferably from about 4 to about 200 mg.

A preferred oral dosage form, such as tablets or
15 capsules, will contain the HMG CoA reductase inhibitor in an amount from about 0.1 to about 100 mg, preferably from about 5 to about 80 mg, and more preferably from about 10 to about 40 mg.

A squalene synthetase inhibitor may be administered
20 with the compounds of formula I within the range of from about 10 mg to about 2000 mg and preferably from about 25 mg to about 200 mg.

A preferred oral dosage form, such as tablets or capsules, will contain the squalene synthetase inhibitor in
25 an amount of from about 10 to about 500 mg, preferably from about 25 to about 200 mg.

The compounds of formula I of the invention can be administered orally or parenterally, such as subcutaneously or intravenously, as well as by nasal application, rectally
30 or sublingually to various mammalian species known to be subject to such maladies, e.g., humans, in an effective amount within the dosage range of about 0.01 µg/kg to about 1000 µg/kg, preferably about 0.1 µg/kg to 100 µg/kg, more preferably about 0.2 µg/kg to about 50 µg/kg (or from about
35 0.5 to 2500 mg, preferably from about 1 to 2000 mg) in a regimen of single, two or four divided daily doses.

The compounds of the formula I can be administered for any of the uses described herein by any suitable means, for

5 example, orally, such as in the form of tablets, capsules,
granules or powders; sublingually; buccally; parenterally,
such as by subcutaneous, intravenous, intramuscular, or
intrasternal injection or infusion techniques (e.g., as
sterile injectable aqueous or non-aqueous solutions or
10 suspensions); nasally, including administration to the
nasal membranes, such as by inhalation spray; topically,
such as in the form of a cream or ointment; or rectally
such as in the form of suppositories; in dosage unit
formulations containing non-toxic, pharmaceutically
15 acceptable vehicles or diluents. The present compounds
can, for example, be administered in a form suitable for
immediate release or extended release. Immediate release
or extended release can be achieved by the use of suitable
pharmaceutical compositions comprising the present
20 compounds, or, particularly in the case of extended
release, by the use of devices such as subcutaneous
implants or osmotic pumps. The present compounds can also
be administered liposomally.

Exemplary compositions for oral administration include
25 suspensions which can contain, for example,
microcrystalline cellulose for imparting bulk, alginic acid
or sodium alginate as a suspending agent, methylcellulose
as a viscosity enhancer, and sweeteners or flavoring agents
such as those known in the art; and immediate release
30 tablets which can contain, for example, microcrystalline
cellulose, dicalcium phosphate, starch, magnesium stearate
and/or lactose and/or other excipients, binders, extenders,
disintegrants, diluents and lubricants such as those known
in the art. The compounds of formula I can also be
35 delivered through the oral cavity by sublingual and/or
buccal administration. Molded tablets, compressed tablets
or freeze-dried tablets are exemplary forms which may be
used. Exemplary compositions include those formulating the

5 present compound(s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG). Such formulations can also include an
10 excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g. Carbopol 934).
15 Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.

Exemplary compositions for nasal aerosol or inhalation administration include solutions in saline which can
20 contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.

Exemplary compositions for parenteral administration
25 include injectable solutions or suspensions which can contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting
30 and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid, or Cremaphor.

Exemplary compositions for rectal administration include suppositories which can contain, for example, a
35 suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.


5 Exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).

It will be understood that the specific dose level and frequency of dosage for any particular subject can be
10 varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate
15 of excretion, drug combination, and severity of the particular condition.

The following working examples serve to better illustrate, but not limit, some of the preferred embodiments of the present invention.


20

Example 1



25 **3,5-dichloro-2-fluoro-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonylmethylaminopyridine**

Compound 1a: 2-Isopropylanisole




30

To a solution of 2-isopropylphenol (30g, 220.3 mmol) in CH₂Cl₂ (300 mL) was added tetrabutylammonium hydrogen

5 sulfate (7.5g, 22.1 mmol). After the entire solid was dissolved, a solution of potassium hydroxide (61.8 g, 1.1 mol in 300 mL H₂O) was added to the previous mixture. After 15 minutes of stirring, methyl iodide (47g, 20.6 mL, 331 mmol) was added. The mixture was left to stir overnight
10 (ca. 15 hours). The organic layer was separated and then washed with brine (2 x 100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The solid material in the concentrate was removed by filtration. The precipitate was washed with hexane (100 mL). The filtrate was concentrated
15 in vacuo to give 32.15 g of yellow oil as a crude product. The crude product was filtered through a pad of silica gel (250 g) and washed with 5 % EtOAc in hexane to give 30.7 g (93%) of compound 1a as a colorless oil.

20 ¹H NMR (500 MHz, CDCl₃, δ) 7.21 (d, 1H, J = 7.7 Hz), 7.16 (t, 1H, J = 7.7 Hz), 6.92 (t, 1H, J = 7.7 Hz), 6.84 (d, 1H, J = 8.3 Hz), 3.82 (s, 3H), 3.27 (septet, 1H, 7 Hz), 1.205 (d, 6H, J = 6.6 Hz)

25 Compound 1b: 3-Isopropyl-4-methoxybenzaldehyde




To a 3-necked flask containing 2-isopropylanisole (14g, 93.2 mmol) was added phosphorus oxychloride (57.6 g, 35 mL, 375.5 mmol). The mixture was heated to 80°C and maintained at this temperature while N,N-dimethylformamide (27.4 g, 29 mL, 374.5 mmol) was slowly added using an addition funnel. After the DMF addition, the mixture was heated to 95°C and
35 maintained at this temperature overnight (ca. 19 h). After cooling to RT, the mixture was poured into a flask

5 containing ice and H₂O (200 mL) and stirred for ca. 15 min.
The product was partitioned with EtOAc (300 mL) and brine
(200 mL). The EtOAc extract was separated, washed with
brine (2 x 150 mL), dried (Na₂SO₄), filtered and concentrated
in vacuo. The crude product was purified by chromatography
10 (250 g silica gel, 10% EtOAc in hexane) to afford 13 g (78%)
of compound 1b as a yellow oil.

¹H NMR (500 MHz, CDCl₃, δ) 9.87 (s, 1H), 7.755 (d, 1H, J =
1.6 Hz), 7.695 (dd, 1H, J = 8.8 Hz, 1.6 Hz), 6.94 (d, 1H, J
15 = 8.3 Hz), 3.91 (s, 3H), 3.31 (septet, 1H, 7 Hz), 1.225 (d,
6H, J = 7.1 Hz)


Compound 1c: 3-Isopropyl-4-methoxyphenol



To a solution of 3-isopropyl-4-methoxybenzaldehyde
(12.5 g, 70 mmol) in MeOH (140 mL) was added concentrated
sulfuric acid (1.2 mL) followed by dropwise addition of 30%
25 by wt aqueous hydrogen peroxide (6g, 20 mL, 176 mmol). The
mixture was left to stir at ambient room temperature. After
3 hours, the mixture was concentrated in vacuo to about 1/3
of the reaction volume. The concentrate was partitioned
between EtOAc (100 mL) and brine (50 mL). The EtOAc extract
30 was washed with brine (50 mL), dried (Na₂SO₄), filtered and
concentrated in vacuo to give 13.5 g of dark oil as crude
product. The crude product was purified by chromatography
(250 g silica gel, 10% EtOAc in hexane) to afford 10.1g
(86%) of compound 1c as a thick oil that eventually
35 solidified.

5 ^1H NMR (500 MHz, CDCl_3 , δ) 6.715 (d, 1H, $J = 2.8$ Hz), 6.705 (d, 1H, $J = 3.3$ Hz), 6.595 (dd, 1H, $J = 8.8$ Hz, 3.3 Hz), 4.44 (s, 1H), 3.77 (s, 3H), 3.27 (septet, 1H, 7 Hz), 1.175 (d, 6H, $J = 7.2$ Hz)

10 Compound 1d: 3,5-Dichloro-2,6-difluoro-4-(3-isopropyl-4-methoxyphenoxy)pyridine




15 To a solution of 3-isopropyl-4-methoxyphenol (0.68 g) and 3,5-dichloro-2,4,6-trifluoropyridine (0.84 g) in DMF (4.0 mL) was added potassium carbonate powder (0.67 g) in one portion. The resulting mixture was stirred at ambient temperature for 1 h. The reaction mixture was diluted with
20 brine, extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried (Na_2SO_4), and concentrated in vacuo to afford compound 1d as an off-white solid (1.15 g, 80%).

25 ^1H NMR (500 MHz, CDCl_3 , δ) 6.87 (d, 1H, $J = 3.3$ Hz), 6.73 (d, 1H, $J = 8.8$ Hz), 6.55 (dd, 1H, $J = 8.8$ Hz, 3.3 Hz), 3.80 (s, 3H), 3.29 (septet, 1H, 7 Hz), 1.18 (d, 6H, $J = 7.2$ Hz).

Compound 1e: 3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonylmethylaminopyridine

30



5

To a solution of 3,5-dichloro-2,6-difluoro-4-(3-isopropyl-4-methoxyphenoxy)pyridine. (584 mg) and glycine methyl ester hydrochloric acid (220 mg) in DMF (5.0 mL) was added potassium carbonate powder (500 mg) in one portion.

10 The resulting mixture was stirred at ambient temperature for 20 hours. The reaction mixture was diluted with brine, extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL x 3), dried (Na_2SO_4), and concentrated. Chromatography with ethyl


15 acetate-hexanes (0 - 50% gradient elution) afforded the title compound as a colorless oil (434 mg, 62%).

^1H NMR (500 MHz, CDCl_3 , δ) 6.89 (d, 1H, $J = 3.3$ Hz), 6.71 (d, 1H, $J = 8.8$ Hz), 6.54 (dd, 1H, $J = 8.8$ Hz, 3.3 Hz), 5.70 (br. t, 1 H, $J = 5$ Hz), 4.21 (d, 2 H, $J = 5$ Hz), 3.80 (s, 3H), 3.78 (s, 3H), 3.28 (septet, 1H, 7 Hz), 1.18 (d, 6H, $J = 7.2$ Hz).

20

Example 2

25



3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-hydroxycarbonylmethylaminopyridine

30

To a solution of 3,5-dichloro-2-fluoro-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonyl-methylaminopyridine (100 mg) in CH_2Cl_2 was added a solution of BBr_3 in CH_2Cl_2 (1 mL, 1.0 M) at ambient temperature. The

35 resulting mixture was stirred for 30 min., poured to

5 stirring water (50 mL), extracted with CH_2Cl_2 (20 mL x 3)
from water, dried (Na_2SO_4) and concentrated to dryness under
reduced pressure. The residue was dissolved in $\text{THF}:\text{MeOH}:\text{H}_2\text{O}$
= 3:1:1 (5 mL), treated with a solution of LiOH in water (1
mL, 1.0 M) and stirred at ambient temperature for 30 min.
10 The reaction mixture was diluted with a 1.0 M solution of
HCl (50 mL), extracted with ethyl acetate (50 mL x 3), dried
(Na_2SO_4) and concentrated under reduced pressure.
Purification by HPLC provided the title compound as a white
solid (80 mg).


15 ^1H NMR (500 MHz, CDCl_3 , δ) 6.85 (d, 1H, $J = 3.3$ Hz), 6.64
(d, 1H, $J = 8.8$ Hz), 6.47 (dd, 1H, $J = 8.8$ Hz, 3.3 Hz), 5.63
(br. t, 1H, $J = 5$ Hz), 4.29 (d, 2H, $J = 5$ Hz), 3.17
(septet, 1H, 7 Hz), 1.23 (d, 6H, $J = 7.2$ Hz).

20

Examples 3-13 were prepared by a similar procedure as
described in Example 1, but with the following variations:

Example 3

25



**3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-
hydroxycarbonylmethylthiopyridine**


30

By use of methyl mercaptoacetate in place of glycine
methyl ester for the preparation of Compound 1e followed by
deprotection as described for example 2.

$(\text{M}-\text{H})^- = 403.87$

35 molecular weight (MW) = 406.26

5

Example 4

10 **3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-**
 (2-hydroxycarbonylethylamino)pyridine


 By use of β -alanine methyl ester in place of glycine
methyl ester for the preparation of Compound 1e followed by
15 deprotection as described for example 2.

(M-H)⁻ = 400.9

MW = 403.24

Example 5

20



3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-
 (2-aminocarbonylmethylamino)pyridine


25

 By use of glycine amide in place of glycine methyl ester
for the preparation of Compound 1e followed by deprotection
as described for example 2.

(M-H)⁻ = 386

30 MW = 388.23

5


Example 6

10 **3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-(1-methyl-1-hydroxycarbonyl)methylaminopyridine**

By use of l-alanine methyl ester in place of glycine methyl ester for the preparation of Compound 1e followed by deprotection as described for example 2.

15 Satisfactory $^1\text{H-NMR}$ and MS data were obtained.
(M-H) $^-$ = 401
MW = 403.24

20

Example 7


25 **3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-(3-hydroxysulfonylpropylamino)pyridine**

30

By use of 3-aminopropylsulfonic acid in place of glycine methyl ester for the preparation of Compound 1e followed by deprotection as described for example 2.

(M-H) $^-$ = 451
MW = 453.32

5


Example 8

10 **3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-(1-hydroxycarbonyl-2-hydroxyethylamino)pyridine**

By use of l-serine methyl ester in place of glycine methyl ester for the preparation of Compound 1e followed by deprotection as described for example 2.

15 $(M+H)^+ = 417$

MW = 419.24

Example 9

20

3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-(3-hydroxycarbonylmethylamino-3-oxopropylamino)pyridine


25 By use of β -alanyl-glycine in place of glycine methyl ester for the preparation of Compound 1e followed by deprotection as described for example 2.

$(M-H)^- = 458$

MW = 460.29

30

5

Example 10


10

3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-(2-hydroxysulfonyl-ethylamino)pyridine

By use of 2-aminoethylsulfonic acid in place of glycine methyl ester for the preparation of Compound 1e followed by deprotection as described for example 2.

15 (M-H)⁻ = 439.29

MW = 437

Example 11

20

3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-(2-hydroxycarbonylmethylamino-2-oxo-1-methylethylamino)-pyridine


25

By use of 1-alanyl-glycine methyl ester in place of glycine methyl ester for the preparation of Compound 1e followed by deprotection as described for example 2.

(M-H)⁻ = 458

30 MW = 560.29

5

Example 12


10

3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-hydroxysulfonylmethylaminopyridine

By use of aminomethanesulfonic acid in place of glycine methyl ester for the preparation of Compound 1e followed by deprotection as described for example 2.

15 (M-H)⁻ = 423

MW = 425.27

Example 13

20

3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-(2-hydroxyethylamino)pyridine


25 By reduction of the methyl ester of 3,5-dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-hydroxycarbonylmethylaminopyridine (example 2), with Dibal-H in THF.

(M-H)⁻ = 423

MW = 425.27


30

5

Example 14

3,5-dichloro-2-fluoro-4-[3-bromo-4-methoxy-phenoxy]-6-methoxycarbonylmethyl-aminopyridine

10 Compound 14a: 3-Ethylphenylboronic acid




To a solution of 3-bromo-1-ethylbenzene (1.0 g) in THF
15 (10 mL) at -78°C under argon was added a solution of n-BuLi
(2.5 M, 2.5 mL) in hexanes in dropwise fashion. The mixture
was stirred at -78°C for 10 min. and treated with 1.35 mL of
tri-isopropylborate (neat) dropwise. The reaction mixture
was allowed to warm up to 10°C over a period of 3 hours
20 while stirring. The mixture was then quenched carefully
with 1 N HCl (100 mL) solution and extracted with ethyl
acetate (100 mL x 2). The combined organic layers were
dried (Na₂SO₄) and concentrated under reduced pressure.
Chromatography with ethyl acetate-hexanes (0-100% gradient
25 elution) provided compound 14a as a white solid (0.4 g).

¹H NMR (500 MHz, CDCl₃, δ) 8.06 (m, 2H), 7.44 (m, 2H), 2.77
(q, 2H, J = 7.0 Hz), 1.32 (t, 3H, J = 7.0 Hz).

30 Compound 14b: 3,5-Dichloro-2,6-difluoro-4-(4-methoxy-
phenoxy)pyridine


5



To a solution of 4-methoxyphenol (1.25 g) and 3,5-dichloro-2,4,6-trifluoropyridine (2.05 g) in DMF (10.0 mL) was added potassium carbonate powder (1.50 g) in one portion. The resulting mixture was stirred at ambient temperature for 3 hours. The reaction mixture was diluted with brine and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried (Na₂SO₄), and concentrated in vacuo to provide compound 14b as a white solid (3.0 g).

¹H NMR (500 MHz, CDCl₃, δ) 6.78 (m, 4H), 3.72 (s, 3H).

20 Compound 14c: 3,5-Dichloro-2,6-difluoro-4-(3-bromo-4-methoxyphenoxy)pyridine




25 To a solution of 3,5-dichloro-2,6-difluoro-4-(4-methoxyphenoxy)pyridine (0.94 g) in CH₂Cl₂ (10 mL) was added neat bromine (1.0 g). The mixture was stirred at ambient temperature for 1 h. The solvent and excess bromine were removed under reduced pressure. Chromatography with ethyl acetate-hexanes (0-50% gradient elution) provides compound 14c (0.25 g).

5 ^1H NMR (500 MHz, CDCl_3 , δ) 7.14 (d, 1H, $J = 2.7$ Hz), 6.82 (m, 2H), 3.87 (s, 3H).

Compound 14d: 3,5-Dichloro-2-fluoro-4-(3-bromo-4-methoxyphenoxy)-6-methoxycarbonylmethylaminopyridine

10




To a solution of 3,5-dichloro-2,6-difluoro-4-(3-bromo-4-methoxyphenoxy)pyridine (250 mg) and glycine methyl ester hydrochloric acid (150 mg) in DMF (2.0 mL) was added
15 potassium carbonate powder (250 mg) in one portion. The resulting mixture was stirred at ambient temperature for 20 hours. The reaction mixture was diluted with brine and extracted with ethyl acetate (50 mL x 2). The combined
20 organic layers were washed with brine (50 mL x 3), dried (Na_2SO_4) and concentrated. Chromatography with ethyl acetate-hexanes (0 - 50% gradient elution) provided the title compound as a white solid (253 mg).

25 ^1H NMR (500 MHz, CDCl_3 , δ) 7.13 (d, 1H, $J = 2.7$ Hz), 6.82 (m, 2H), 5.70 (br. t, 1H, $J = 5.0$ Hz), 4.24 (d, 2H, $J = 5$ Hz), 3.87 (s, 3H), 3.81 (s, 3H).

Example 15

30




5

**3,5-Dichloro-2-fluoro-4-[3-(3-ethylphenyl)-4-methoxy-
phenoxy]-6-methoxycarbonylmethylaminopyridine**

To a solution of 3,5-dichloro-2,6-difluoro-4-(3-bromo-
10 4-methoxyphenoxy)-6-methoxycarbonyl-methylaminopyridine (253
mg) and 3-ethylphenylboronic acid (100 mg) in THF (10.0 mL)
was added a solution of sodium carbonate (2.0 M in water,
1.0 mL). The resulting mixture was degassed with argon,
treated with tetrakis(triphenylphosphine) palladium (30 mg)
15 and stirred at reflux in dark for 18 hours. Cooled reaction
mixture was diluted with brine, neutralized with 1 N HCl and
extracted with ethyl acetate (50 mLx 3). The combined
organic layers were dried (Na₂SO₄) and concentrated.
Chromatography with ethyl acetate-hexanes (0 - 50% gradient
20 elution) afforded the title compound as a light yellow oil
(180 mg).

¹H NMR (500 MHz, CDCl₃, δ) 7.32 (m, 3H), 7.19 (m, 1H), 6.90
(m, 2H), 6.82 (m, 1H), 5.69 (br. t, 1 H, J = 5 Hz), 4.21 (d,
25 2 H, J = 5 Hz), 3.80 (s, 3H), 3.78 (s, 3H), 2.69 (q, 2H, 7
Hz), 1.27 (t, 3H, J = 7 Hz).

Example 16



30

**3,5-Dichloro-2-fluoro-4-[3-(3-ethylphenyl)-4-hydroxy-
phenoxy]-6-hydroxycarbonylmethylaminopyridine**


5 To a solution of 3,5-dichloro-2-fluoro-4-[3-(3-ethylphenyl)-4-methoxyphenoxy]-6-methoxycarbonylmethyl-aminopyridine (50 mg) in CH_2Cl_2 was added a solution of BBr_3 in CH_2Cl_2 (0.5 mL, 1.0 M) at ambient temperature. The resulting mixture was stirred for 30 min. The reaction
10 mixture was diluted with a 1.0 M solution of HCl (50 mL), extracted with ethyl acetate (50 mL x 3), dried (Na_2SO_4) and concentrated under reduced pressure. Purification by HPLC afforded the title compound as a yellow oil (32 mg).

15 ^1H NMR (500 MHz, CDCl_3 , δ) 7.41 (m, 1H), 7.26 (m, 3H), 6.92 (m, 1H), 6.80 (m, 2H), 5.63 (br. t, 1 H, $J = 5$ Hz), 5.18 (br. s, 2H), 4.29 (d, 2 H, $J = 5$ Hz), 2.70 (q, 2H, 7 Hz), 1.27 (t, 3H, $J = 7$ Hz).

20 Examples 17-21 were prepared by a similar procedure as described in Examples 14 through 16, but with the following variations.

Example 17

25



3,5-Dichloro-2-fluoro-4-(3-phenyl-4-hydroxyphenoxy)-6-hydroxycarbonylmethylaminopyridine


30

By use of phenylboronic acid in place of 3-ethylphenylboronic acid in example 15 followed by deprotection as described for example 16.

(M-H)⁻ = 421

35 MW = 423.23

5

Example 18

10 **3,5-Dichloro-2-fluoro-4-[3-(3-bromo-4-hydroxyphenoxy)-6-**
 hydroxycarbonylmethyl-aminopyridine

 By direct deprotection of 3,5-dichloro-2-fluoro-4-(3-
bromo-4-methoxy-phenoxy)-6-methoxycarbonylmethylamino-
15 pyridine using the procedure as described for example 16.

(M-H)⁻ = 424.8

MW = 426.03

5

COC(=O)Nc1nc(F)c(Cl)c(Oc2cc(OC)c(c2-c3ccc(Cl)cc3)O1)c1

10

15

$$MW = 485.73$$
O=C(O)CNc1nc(F)c(Cl)c(Oc2cc(Cl)ccc2O)c1


20

25

$$(M-H)^- = 455$$

- 56 -

5

Example 21


10

3,5-Dichloro-2-fluoro-4-(4-hydroxynaphthoxy)-6-hydroxycarbonylmethylamino-pyridine

By use of 4-methoxynaphthol in place of 4-methoxyphenol using the procedure as described to prepare compound 14b followed by deprotection as described for example 2.

15 (M-H)⁻ = 395

MW = 397.19

Example 22

20


3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonylmethoxypyridine

25 To a solution of 3,5-dichloro-2,6-difluoro-4-(3-isopropyl-4-methoxyphenoxy)pyridine (100 mg) and methyl glycolate (neat, 25 μ L) in THF (2.0 mL) was added a 60% oil dispersion of sodium hydride (10 mg) in one portion. The resulting mixture was stirred at ambient temperature for 30
30 min. The reaction mixture was diluted with brine, neutralized with 1 N HCl, extracted with CH₂Cl₂ (50 mLx 2),

5 dried (Na_2SO_4) and concentrated in vacuo to afford the title compound as a colorless oil (120 mg).

^1H NMR (500 MHz, CDCl_3 , δ) 6.87 (d, 1H, $J = 2.7$ Hz), 6.71 (d, 1H, $J = 8.8$ Hz), 6.52 (dd, 1H, $J = 8.8$ Hz, 2.7 Hz), 4.94 (s, 2 H), 3.78 (s, 3H), 3.76 (s, 3H), 3.28 (septet, 1H, 7 Hz), 1.18 (d, 6H, $J = 7$ Hz).

Example 23




3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-hydroxycarbonylmethoxypyridine

20 To a solution of 3,5-dichloro-2-fluoro-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonylmethoxy-pyridine (120 mg) in CH_2Cl_2 (3.0 mL) was added a solution of BBr_3 in CH_2Cl_2 (1 mL, 1.0 M) at ambient temperature. The resulting mixture was stirred for 2 h, poured to stirring water (50 mL),
25 extracted with CH_2Cl_2 (20 mL x 3) from water, dried (Na_2SO_4) and concentrated to dryness under reduced pressure. The residue was dissolved in $\text{THF}:\text{MeOH}:\text{H}_2\text{O} = 3:1:1$ (5 mL), treated with a solution of LiOH in water (1 mL, 1.0 M) and stirred at ambient temperature for 30 min. The reaction
30 mixture was diluted with a 1.0 M solution of HCl (50 mL), extracted with ethyl acetate (50 mL x 3), dried (Na_2SO_4) and concentrated under reduced pressure. Purification by HPLC afforded the title compound as a colorless oil (80 mg).

5 ^1H NMR (500 MHz, CDCl_3 , δ) 6.86 (d, 1H, $J = 2.7$ Hz), 6.66 (d, 1H, $J = 8.8$ Hz), 6.47 (dd, 1H, $J = 8.8$ Hz, 2.7 Hz), 6.13 (br. s, 2 H), 5.01 (s, 2 H), 3.17 (septet, 1H, 7 Hz), 1.23 (d, 6H, $J = 7.2$ Hz).

10 Examples 24-27 were prepared by a similar procedure as described in Example 22, but with the following variations.

Example 24



3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-methoxycarbonylmethoxypyridine


20 Obtained via purification of the intermediate before treatment with LiOH in the procedure for preparation of example 23.

(M-H) $^-$ = 401.8

MW = 409.23

25

Example 25



3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-methoxyphenoxy)-6-hydroxycarbonylmethoxypyridine


5 The title compound was obtained by LiOH hydrolysis of example 22.

(M-H)⁻ = 401.8

MW = 404.23

10

Example 26



15


3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenoxy)-6-aminocarbonylmethoxypyridine

Prepared by use of glycolamide in place of methyl glycolate in the procedure for example 22, followed by BBr₃ deprotection, as described for example 23.

20 (M-H)⁻ = 386.9

MW = 389.21

Example 27



25


3,5-Dichloro-2-fluoro-4-(3-bromo-4-methoxyphenoxy)-6-methoxycarbonylmethoxypyridine

30 Prepared by use of 4-(3-bromo-4-methoxyphenoxy)-3,5-dichloro-2,6-difluoropyridine in place of 3,5-dichloro-2,6-difluoro-4-(3-isopropyl-4-methoxyphenoxy)pyridine in the procedure described for example 22.

5 (M+H)⁺ = 455.7

MW = 455.07

Example 28



10


3,5-Dichloro-2-fluoro-4-(3-phenyl-4-hydroxyphenoxy)-6-hydroxycarbonylmethoxypyridine

15 Prepared by use of 3,5-dichloro-2,6-difluoro-4-(3-bromo-4-methoxyphenoxy)-6-methoxycarbonylmethoxypyridine in place of 3,5-dichloro-2,6-difluoro-4-(3-bromo-4-methoxyphenoxy)-6-methoxycarbonyl-methylaminopyridine in the procedure described for example 17.

20 (M-H)⁻ = 421.9

MW =

Example 29



25

3,5-Dichloro-2-fluoro-4-[3-(3-chlorophenyl)-4-methoxyphenoxy]-6-methoxycarbonylmethoxypyridine

30 Prepared by use of 3,5-dichloro-2,6-difluoro-4-(3-bromo-4-methoxyphenoxy)-6-methoxycarbonylmethoxypyridine in


5 place of 3,5-dichloro-2,6-difluoro-4-(3-bromo-4-methoxyphenoxy)-6-methoxycarbonyl-methylaminopyridine in the procedure described for example 19.

(M-H)⁻ = 484.8

MW = 486.71

10

Example 30




15 **3,5-Dichloro-2-fluoro-4-[3-(3-ethylphenyl)-4-methoxyphenoxy]-6-methoxycarbonylmethoxypyridine**

Prepared by use of 3,5-dichloro-2,6-difluoro-4-(3-bromo-4-methoxyphenoxy)-6-methoxycarbonylmethoxypyridine in
20 place of 3,5-dichloro-2,6-difluoro-4-(3-bromo-4-methoxyphenoxy)-6-methoxycarbonyl-methylaminopyridine in the procedure described for example 15.

MW = 480.32

25

Example 31



30 **3,5-Dichloro-2-fluoro-4-[3-(3-ethylphenyl)-4-hydroxyphenoxy]-6-hydroxycarbonylmethoxypyridine**

5


Prepared by deprotection of example 30 using the procedure described for example 16.

$(M-H)^- = 449.8$

MW = 452.27

10

Example 32



15


3,5-Dichloro-2-fluoro-4-[3-(3-chlorophenyl)-4-hydroxyphenoxy]-6-hydroxycarbonylmethoxypyridine

Prepared by deprotection of example 29 using the procedure described for example 20.

20 $(M-H)^- = 457.5$

MW = 458.66

Example 33



25

3,5-Dichloro-2-fluoro-4-[3-bromo-4-hydroxyphenoxy]-6-hydroxycarbonylmethoxypyridine


30

Prepared by deprotection of example 27 using the procedure described for example 16.

$(M-H)^- = 425.72$

5 MW = 427.01

Example 34




10

3,5-dichloro-4-(3-isopropyl-4-hydroxyphenoxy)-6-hydroxycarbonylmethylaminopyridine

Compound 34a: 3,5-Dichloro-2-ethylthio-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonylmethylaminopyridine

15



To a solution of 3,5-dichloro-2-fluoro-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonylmethylaminopyridine (200 mg) in DMF was added ethylthiol (0.1 mL, neat) and potassium carbonate powder (100 mg) at ambient temperature. The resulting mixture was stirred for 4 h at ambient temperature and 4 h at 70°C. Cooled reaction mixture was diluted with brine (100 mL) and extracted with ethyl acetate (50 mL x 3). Combined organic layers were washed with brine (50 mL x 3), dried (Na₂SO₄) and concentrated under reduced pressure. Chromatography with ethyl acetate-hexanes (0-25% gradient elution) afforded compound 34a (130 mg).

20


25

30

¹H NMR (500 MHz, CDCl₃, δ) 6.90 (d, 1H, J = 2.7 Hz), 6.69 (d, 1H, J = 8.8 Hz), 6.49 (dd, 1H, J = 8.8 Hz, 2.7 Hz), 5.53

5 (br. t, 1 H, $J = 5$ Hz), 4.24 (d, 2 H, $J = 5$ Hz), 3.79 (s, 3H), 3.78 (s, 3H), 3.28 (septet, 1H, 7 Hz), 3.11 (q, 2H, $J = 7$ Hz), 1.38 (t, 3H, $J = 7$ Hz), 1.19 (d, 6H, $J = 7$ Hz).

Compound 34b: 3,5-Dichloro-4-(3-isopropyl-4-hydroxy-phenoxy)-6-hydroxycarbonylmethylaminopyridine



To a suspension of Raney-Nickel (ca. 0.3 g) in ethanol (2 mL) was added a solution of 3,5-dichloro-2-ethylthio-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonyl-methylaminopyridine (122 mg) in ethanol (3 mL) at ambient temperature. The resulting mixture was stirred at reflux for 3 hours. Cooled reaction mixture was filtered through celite. Filtrate was extracted with ethyl acetate (50 mL x 3) from brine, dried (Na_2SO_4) and concentrated to dryness under reduced pressure. The residue was dissolved in CH_2Cl_2 (3 mL), treated with a solution of BBR_3 in CH_2Cl_2 (1 mL, 1.0 M), stirred at ambient temperature for 30 min. The reaction mixture was diluted with brine (50 mL), extracted with CH_2Cl_2 (50 mL x 3), dried (Na_2SO_4) and concentrated under reduced pressure. Purification by HPLC afforded the title compound (24 mg).

30 ^1H NMR (500 MHz, CD_3OD , δ) 8.02 (s, 1H), 6.71 (d, 1H, $J = 2.7$ Hz), 6.64 (d, 1H, $J = 8.8$ Hz), 6.41 (dd, 1H, $J = 8.8$ Hz, 2.7 Hz), 4.15 (s, 2 H), 3.23 (septet, 1H, 7 Hz), 1.17 (d, 6H, $J = 7$ Hz).

5

CC(C)c1ccc(O)cc1Oc2c(Cl)c(Cl)c(OC)c(NCC(=O)O)c2

10

15


20

25

30


5 ^1H NMR (500 MHz, CD_3OD , δ) 6.70 (d, 1H, $J = 3.3$ Hz), 6.62 (d, 1H, $J = 8.8$ Hz), 6.40 (dd, 1H, $J = 8.8$ Hz, 3.3 Hz), 4.11 (s, 2H), 3.91 (s, 3H), 3.22 (septet, 1H, 7.2 Hz), 1.16 (d, 6H, $J = 7.2$ Hz).

10

Example 36

15 **3,5-Dichloro-2-hydroxy-4-(3-isopropyl-4-hydroxyphenoxy)-6-hydroxycarbonylmethylaminopyridine**

Compound 36a: 2-Benzoyloxy-3,5-dichloro-6-fluoro-4-(3-isopropyl-4-methoxyphenoxy)pyridine:



20


To a solution of 3,5-dichloro-2,6-difluoro-4-(3-isopropyl-4-methoxyphenoxy)pyridine (267 mg) and benzyl alcohol (neat, 100 μL) in THF (2.0 mL) was added a 60% oil dispersion of sodium hydride (50 mg) in one portion. The resulting mixture was stirred at ambient temperature for 30 min. The reaction mixture was diluted with brine, neutralized with 1 N HCl (50 mL), extracted with CH_2Cl_2 (50 mLx 2), dried (Na_2SO_4) and concentrated.

30 Chromatography with ethyl acetate-hexanes (0-25% gradient elution) afforded compound 36a as a colorless oil (240 mg).

5 ^1H NMR (500 MHz, CDCl_3 , δ) 7.49 (d, 2H, $J = 7.0$ Hz), 7.39 (t, 2H, $J = 7.0$ Hz), 7.35 (t, 1H, $J = 7.0$ Hz), 6.88 (d, 1H, $J = 2.7$ Hz), 6.72 (d, 1H, $J = 8.8$ Hz), 6.53 (dd, 1H, $J = 8.8$ Hz, 2.7 Hz), 5.44 (s, 2H), 3.79 (s, 3H), 3.29 (septet, 1H, 7 Hz), 1.18 (d, 6H, $J = 7$ Hz).

10

Compound 36b: 2-Benzyloxy-3,5-dichloro-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonylamino pyridine




15

To a solution of 2 benzyloxy-3,5-dichloro-6-fluoro-4-(3-isopropyl-4-methoxyphenoxy)pyridine (98 mg) in DMSO was added glycine methyl ester hydrochloric acid salt (108 mg) and potassium carbonate (200 mg). The mixture was stirred at 100°C for 2 hours. Cooled reaction mixture was diluted with 1 N HCl (50 mL), extracted with ethyl acetate (50 mL x 2). Combined extracts were washed with 1 N HCl (50 mL), dried (Na_2SO_4) and concentrated. Chromatography with ethyl acetate-hexanes (0-100% gradient elution) afforded compound 36b as a colorless oil (60 mg).

20 ^1H NMR (500 MHz, CDCl_3 , δ) 7.44 (d, 2H, $J = 7.0$ Hz), 7.37 (t, 2H, $J = 7.0$ Hz), 7.32 (t, 1H, $J = 7.0$ Hz), 6.90 (d, 1H, $J = 2.7$ Hz), 6.70 (d, 1H, $J = 8.8$ Hz), 6.53 (dd, 1H, $J = 8.8$ Hz, 2.7 Hz), 5.46 (t, 1H, $J = 5.0$ Hz.), 5.40 (s, 2H), 4.19 (d, 2H, $J = 5.0$ Hz), 3.78 (s, 3H), 3.77 (s, 3H), 3.29 (septet, 1H, 7 Hz), 1.19 (d, 6H, $J = 7$ Hz).

35 Compound 36c: 3,5-Dichloro-2-hydroxy-6-hydroxycarbonyl-amino-4-(3-isopropyl-4-hydroxyphenoxy)pyridine


5



To a solution of 2 benzyloxy-3,5-dichloro-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonylamino-pyridine (60 mg) in CH_2Cl_2 (5.0 mL) was added a solution of BBr_3 in CH_2Cl_2 (2 mL, 1.0 M) at ambient temperature. The resulting mixture was stirred for 1.5 hours, poured to stirring water (50 mL), extracted with CH_2Cl_2 (20 mL x 3) from 1 N HCl (50 mL, major solubility problem), dried (Na_2SO_4) and concentrated to dryness under reduced pressure. The residue was dissolved in THF (3 mL), treated with a solution of LiOH in water (1 mL, 1.0 M) and stirred at ambient temperature for 3 hours. The reaction mixture was diluted with a 1.0 M solution of HCl (50 mL), extracted with ethyl acetate (50 mL x 3), dried (Na_2SO_4) and concentrated under reduced pressure. Purification by HPLC afforded the title compound as a white solid (5 mg).

^1H NMR (500 MHz, CD_3OD , δ) 6.71 (d, 1H, $J = 2.7$ Hz), 6.62 (d, 1H, $J = 8.8$ Hz), 6.41 (dd, 1H, $J = 8.8$ Hz, 2.7 Hz), 4.13 (s, 2 H), 3.23 (septet, 1H, 7 Hz), 1.16 (d, 6H, $J = 7.2$ Hz).

Example 37




30

5 **2-Amino-3,5-dichloro-6-hydroxycarbonylmethylamino-4-(3-isopropyl-4-hydroxyphenoxy)pyridine**

Compound 37a: 2-Amino-6-benzylaminocarbonylmethylamino-3,5-dichloro-4-(3-isopropyl-4-hydroxyphenoxy)pyridine.


10



To a solution of 3,5-dichloro-2-fluoro-4-(3-isopropyl-4-methoxyphenoxy)-6-methoxycarbonylmethylamino-
15 pyridine (80 mg) and benzyl amine (neat, 100 μ L) in methanol (2.0 mL) was added potassium carbonate (200 mg) in one portion. The resulting mixture was stirred at 80°C for 20 hours. Cooled reaction mixture was diluted with brine, extracted with ethyl acetate (50 mL x 2), dried (Na_2SO_4), and
20 concentrated. The residue was dissolved in CH_2Cl_2 (5.0 mL) and treated with a solution of BBr_3 in CH_2Cl_2 (2 mL, 1.0 M) at ambient temperature. The resulting mixture was stirred for 2 hours, poured to stirring 1 N HCl (50 mL), extracted with ethyl acetate (20 mL x 3) from 1 N HCl (50 mL, major
25 solubility problem, dried (Na_2SO_4) and concentrated to dryness under reduced pressure. Purification by HPLC afforded compound 37a (35 mg).

^1H NMR (500 MHz, CD_3OD , δ) 7.25 (m, 5H), 6.70 (d, 1H, $J = 2.7$
30 Hz), 6.59 (d, 1H, $J = 8.8$ Hz), 6.38 (dd, 1H, $J = 8.8$ Hz, 2.7 Hz), 4.41 (s, 2 H), 4.03 (s, 2H), 3.20 (septet, 1H, 7Hz), 1.14 (d, 6H, $J = 7.2$ Hz).

- 5 Compound 37b: 2-Amino-3,5-dichloro-4-(3-isopropyl-4-hydroxy-phenoxy)-6-hydroxycarbonylaminopyridine




- 10 To a solution of 2-amino-6-benzylaminocarbonyl-methylamino-3,5-dichloro-4-(3-isopropyl-4-hydroxy-phenoxy)pyridine (35 mg) in methanol (5 mL) was added concentrated sulfuric acid (0.3 mL). The resulting mixture was stirred at reflux for 18 hours. Cooled reaction mixture
15 was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 2). Combined extracts were dried (Na_2SO_4) and concentrated under reduced pressure to afford the methyl ester as a light yellow oil (25 mg). This intermediate was dissolved in methanol (3.0 mL), treated with a solution of
20 LiOH in water (1.0M, 1.0 mL), stirred at ambient temperature for 1h, diluted with 1N HCl (50 mL), extracted with EtOAc (50 mL x 2), dried (Na_2SO_4) and concentrated. Preparative HPLC purification afforded the title compound as a white solid (23 mg).

25

^1H NMR (500 MHz CD_3OD , δ) 6.71 (d, 1H, $J = 2.7$ Hz), 6.62 (d, 1H, $J = 8.8$ Hz), 6.41 (dd, 1H, $J = 8.8$ Hz, 2.7 Hz), 4.13 (s, 2 H), 3.23 (septet, 1H, 7 Hz), 1.15 (d, 6H, $J = 7.2$ Hz).


30

5

Example 38

10 **3,5-Dichloro-2-fluoro-4-[3-(phenethylaminocarbonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylmethylaminopyridine**

Compound 38a: 3,5-dichloro-2,6-difluoro-4-[3-formyl-4-methoxyphenoxy]pyridine




15

3,5-dichloro-2,6-difluoro-4-(4-methoxyphenoxy)-pyridine (0.31g, 1 mmol) was dissolved in 7 mL of methylenechloride and cooled to -58°C under argon. Dichloromethyl methyl ether (0.18 mL, 2mmol) was added, followed by dropwise addition of an 1.0 M tin chloride solution in methylenechloride (6 mL). The reaction mixture was stirred for 5 hrs at 0°C then quenched by the addition of 3 mL of 1N HCl. After stirring for 30 minutes, product was extracted 2X with 50 mL portions of methylene chloride. The product was purified by silica gel chromatography using 10% ethyl acetate in hexanes. The appropriate fractions were combined and concentrated to yield 0.26g (77%) of compound 38a. M.P. 111-112°C.

30

¹H NMR (CDCl₃) δ 7.25-7.20 (2H, m), 7.02 (1H, d, J 8.78 Hz), 3.94 (3H, s), 10.41(1H, s)

- 5 Compound 38b: 3,5-Dichloro-2,6-difluoro-4-[3-(hydroxy-carbonyl)-4-methoxyphenoxy]pyridine



- 10 Sulfamic acid (0.74 mL, of 1M solution) was added to a 1 mL THF solution of compound 38a (0.1308g, 0.392 mmol). This was cooled to 5°C and sodium chlorite (71 mg, 57.6 mg) in 0.4 mL of water was added dropwise. After addition, the reaction was stirred at room temperature for 1 hr, diluted
15 with 100 mL of CH₂Cl₂ and 4 mL of water. The organic layer was separated, washed with water, brine, dried (Na₂SO₄), and concentrated in vacuo to yield 0.133 g of compound 38b as a white solid. M.P. 141-149°C.

- 20 ¹H NMR (CDCl₃) 7.57 (1H, d J 3.30Hz), 7.25 (1H, dd J 9.35, 3.30 Hz), 7.09 (1H, J 8.80 Hz), 4.09 (3H, s)

Compound 38c: 3,5-Dichloro-2,6-difluoro-4-[3-(phenethyl-aminocarbonyl)-4-methoxyphenoxy]pyridine

25




- Compound 38b (50 mg, 0.143 mmol), phenethylamine (23.2 mg, 0.185 mmol), hydroxybenzotriazole (21.6 mg, 0.16
30 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbo-diimide HCl were stirred in 2mL of methylene chloride and 0.2 mL of DMF for 1 hr. The reaction mixture was diluted with 20 mL of methylenechloride and the organic solution was washed

5 with water (2x), brine, dried (Na_2SO_4), filtered and concentrated to yield 62.5 mg (96%) of compound 38c as a foam.


^1H NMR(CDCl_3) δ 7.90 (1H, br s), 7.58 (1H, d, J 4.30 Hz),
10 7.28-7.25 (2H, m), 7.19-7.17 (3H, m), 7.01 (1H, dd, J 3.30, 9.35 Hz), 6.85 (1H, d 8.80 Hz), 3.68-3.65 (5H, m), 2.83 (2H, t, 7.15 Hz).

Compound 38d: 3,5-Dichloro-2-fluoro-4-[3-(phenethylamino-carbonyl)-4-methoxyphenoxy]-6-methoxycarbonylmethylamino
15 pyridine



20 3,5-Dichloro-2,6-difluoro-4-[3-(phenethylamino-carbonyl)-4-methoxyphenoxy]pyridine (64.7 mg), glycine methyl ester HCl (35.2 mg) and potassium carbonate (58 mg) were stirred at room temperature for 2 hrs then at 50°C for 30 minutes. The reaction was diluted with 50 mL of
25 ethylacetate, washed with water, brine, dried with Na_2SO_4 , filtered and concentrated to yield 62.5 mg of compound 38d.

Compound 38e: 3,5-dichloro-2-fluoro-4-[3-(phenethylamino-carbonyl)-4-hydroxyphenoxy]-6-hydroxycarbonyl methylamino
30 pyridine




5 Compound 38d (62.5 mg) was dissolved in 1 mL of CH_2Cl_2 under argon and cooled to -50°C . Boron tribromide (0.1mL) was added and the reaction mixture was stirred at ambient temperature for 4 hrs. The reaction mixture was diluted with 10 mL of methylene chloride, then quenched by the
10 addition of 2g of cracked ice. MeOH was added and the reaction mixture was concentrated in vacuo. The crude reaction mixture was purified by preparative HPLC. The appropriate fractions were concentrated in vacuo to yield 22mg the title compound as a white solid.

15

^1H NMR(CD_3OD) δ 7.27- 7.21(6 H, m), 7.05 (1H, dd, J3.30, 9.35 Hz), 3.56 (2H, t, J 7.15 Hz), 2.87 (2H, J7.70 Hz) $[\text{M}+\text{H}]^+$ 494

Example 39

20



25


3,5-Dichloro-2-fluoro-4-[3-(phenethylamino-carbonyl)-4-hydroxyphenoxy]-6-hydroxycarbonyl ethylamino pyridine.

The title compound was prepared in the same manner as in Example 38. However, during the preparation of Compound 38d, β -alanine methyl ester HCl was substituted for glycine
30 methyl ester HCl.

^1H NMR(CD_3OD) δ 7.27-7.18 (6 H, m), 7.02 (1H, dd, J 2.63, 8.78 Hz), 2.87 (2H, t, J 7.03 Hz), 2.64 (2H, t, J 6.59 Hz). $[\text{M}+\text{H}]^+$ 509

35

5


Example 40

10 **3,5-Dichloro-2-fluoro-4-[3-(phenylamino-carbonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylmethylamino pyridine**

The title compound was prepared in the same manner as described in Example 38. However, during the preparation of
15 Compound 38c, aniline was substituted for phenethylamine.

¹H NMR(CD₃OD) δ 7.61 (2H, d, J 8.35Hz), 7.53 (1H, d, J 3.07 Hz), 7.35 (2H, t, J 7.47), 7.15 (1H, t, 7.25), 7.09-7.06 (1H, m), 7.00-6.96 (1H, m). [M-H]⁻ 464

20

Example 41


25 **3,5-Dichloro-2-fluoro-4-[3-(phenylamino-carbonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylethylamino pyridine**

The title compound was prepared in the same manner as described in Example 38. However, during the preparation of
30 Compound 38c and 38d, phenethylamine and glycine methyl ester were replaced by aniline and β-alanine methyl ester HCl respectively.

5 ^1H NMR(CD_3OD) δ 7.61 (2H, d, J 8.25 Hz), 7.52 (1H, d, J 2.76 Hz), 7.35 (2H, t, 8.24 Hz), 7.15 (1H, 7.22 Hz), 7.06 (1H, dd, J 3.29, 9.35 Hz), 6.96 (1H, d, J 8.80 Hz) $[\text{M}+\text{H}]^+$ 480

Example 42

10



3,5-Dichloro-2-fluoro-4-[3-(phenoxy)-4-hydroxyphenoxy]-6-hydroxycarbonylmethylaminopyridine

15

Compound 42a: 3,5-Dichloro-2,6-difluoro-4-(3-hydroxy-4-methoxyphenoxy)pyridine

20 A solution of 3,5-Dichloro-2,6-difluoro-4-(3-formyl-4-methoxyphenoxy)pyridine (0.67g, 2mmol) and 70% MCPBA (0.64g, 2.6mmol) in 8ml of chloroform was stirred at room temperature overnight. The reaction mixture was diluted with 200 ml of ethyl acetate and washed with 5% aqueous sodiumhydrosulfite (4X), brine, dried (Na_2SO_4), filtered and
25 concentrated. The crude formate was dissolved in 20 ml of ethanol and 20 ml of 4N HCl in dioxane and stirred at room temperature for 2 hrs. The crude reaction mixture was concentrated, dissolved in methylene chloride (200ml) and
30 washed with saturated aqueous NaHCO_3 (3X), brine, dried (Na_2SO_4) and concentrated to provide compound 42a in 90% yield.

5 ^1H (CDCl_3) 6.77 (1H, d J 8.80 Hz), 6.56 (1H, d J 2.75), 6.35 (1H, dd J 3.30 7.25), 3.88 (3H, s 3.88)

Compound 42b: 3,5-Dichloro-2,6-difluoro-4-(3-phenoxy-4-methoxyphenoxy)pyridine

10

3,5-Dichloro-2,6-difluoro-4-(3-hydroxy-4-methoxyphenoxy) pyridine (540mg, 1.7 mmol), phenylboronic acid (513 mg, 4.2 mmol), copper acetate (310mg, 1.7 mmol), pyridine (0.65ml), triethyl amine (0.98ml) and dried powdered molecular sieves (2g) were stirred as a slurry in 30 ml of methylene chloride overnight. The reaction mixture was filtered and the filtrate was concentrated to about 4ml. Product was purified by silica gel chromatography using 7% ethyl acetate in hexanes. The appropriate fractions were combined and concentrated to give 440mg (64%) of compound 42b. M.P. 90-94C.

15 ^1H (CDCl_3) 7.33 (2H, app t 8.2Hz), 7.10 (1H, t 7.4Hz), 6.97 (2H, d 7.7 Hz), 6.92 (1H, d 8.80), 6.64 (1H, d 2.75 Hz), 6.57 (1H, dd 3.30 9.08 Hz), 3.83 (3H s)

Compound 42c: 3,5-Dichloro-2-fluoro-4-(3-phenoxy-4-methoxyphenoxy)-6-methoxycarbonylmethylamino pyridine

30 Compound 42c was prepared in the same manner as described for compound 38d, except that 3,5-dichloro-2,6-difluoro-4-(3-phenoxy-4-methoxyphenoxy)pyridine was substituted for 3,5-dichloro-2,6-difluoro-4-[3-(phenethylaminocarbonyl)-4-methoxyphenoxy pyridine.

5 Compound 42c was obtained in 85% yield and was carried to the next step without further purification.

Compound 42d: 3,5-Dichloro-2-fluoro-4-(3-phenoxy-4-hydroxy-phenoxy)-6-hydroxycarbonylmethylaminopyridine


10

Compound 42d was prepared in the same manner as described for compound 38e.

¹H (CD₃OD) 7.31 (2H, app t 8.25 Hz), 7.05 (1H, t 7.70 Hz), 6.93 (2H, app d 7.70 Hz), 6.89 (1H, d 6.87 Hz), 6.55 (1H, dd 2.75 8.80 Hz), 6.48 (1H, d 2.75 Hz), 4.09 (2H, s)

15

Example 43



20

3,5-Dichloro-2-fluoro-4-[3-(parafluorophenaminosulfonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylmethylaminopyridine.

Compound 43a: 3,5-Dichloro-2,6-difluoro-4[3-(hydroxy-sulfonyl)-4-methoxyphenoxy]pyridine

25

3,5-Dichloro-2,6-difluoro-4-(4-methoxyphenoxy)pyridine (1.5g, 4.9 mmol) and chlorosulfonic acid (0.39 ml, 5.8 mmol) were stirred in 5 ml of methylene chloride overnight. The resulting solid was filtered and washed with cold CH₂Cl₂. Compound 43a was obtained as solid in 70% yield.

30

- 5 ^1H (DMSO- d_6) 7.36 (1H, d 3.51 Hz), 7.01-6.95 (2H, m), 3.75 (3H, s)

Compound 43b: 3,5-Dichloro-2,6-difluoro-4[3-(p-fluorophenyl-aminosulfonyl)-4-methoxyphenoxy]pyridine

- 10 Oxalyl chloride (2M in CH_2Cl_2 , 0.2ml) was added to compound 43a (74.4 mg, 0.2 mmol, in 3 ml of CH_2Cl_2 followed by the addition of catalytic DMF. The reaction was stirred at ambient temperature for 2 hrs. N-Methylmorpholine (.088ml, 0.8 mmol) was then added followed by the addition of 4-fluoroaniline (.076 ml, 0.8 mmol). The reaction
15 mixture was stirred overnight, diluted with methylene chloride, and washed with saturated aqueous NaHCO_3 . The organic layer was dried with Na_2SO_4 , filtered and concentrated. Compound 43b was purified by reverse phase preparative HPLC (42% yield).

- 20 Compound 43c: 3,5-Dichloro-2-fluoro-4-[3-(p-fluorophenyl-aminosulfonyl)-4-methoxyphenoxy]-6-methoxycarbonylmethyl-aminopyridine

- 3,5-Dichloro-2,6-difluoro-4[3-(p-fluoro-phenylaminosulfonyl)-4-methoxyphenoxy]pyridine (27.5 mg),
25 glycine methylester HCl (14.5 mg) and potassium carbonate (24 mg) were stirred at room temperature overnight. The reaction was diluted with 25 ml of methylene chloride, washed with water, brine, dried with NaSO_4 , filtered and concentrated to yield 26.9 mg (85%) of compound 43c.

- 30 Compound 43d: 3,5-Dichloro-2fluoro-4[3-(p-fluorophenyl-aminosulfonyl)4-hydroxyphenoxy]-6-methoxycarbonyl-methylamino-pyridine


5 3,5-Dichloro-2-fluoro-4-[3-(p-fluorophenylamino-sulfonyl)-4-methoxyphenoxy]pyridine (26.9 mg) was dissolved in 1 ml of methylene chloride and cooled to about -50°C under argon. Boron tribromide (0.05 ml) was added and the reaction was stirred at 0°C for 2 hrs. The reaction was
10 diluted with 10ml of CH₂Cl₂, then quenched by the addition of about 1 g of cracked ice. MeOH (5 ml) was added and the reaction was concentrated in vacuo. The concentration from methanol was repeated 2X more.

Compound 43e: 3,5-Dichloro-2-fluoro-4-[3-(p-fluorophenyl-
15 aminosulfonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylamino-methylpyridine

3,5-Dichloro-2-fluoro-4[3-(p-fluorophenyl-aminosulfonyl)-4-hydroxyphenoxy]6-methoxycarbonyl methyl-aminopyridine was stirred for 2 hours at room temperature
20 in 2ml of THF and 0.5 ml of 1N LiOH, The reaction was acidified to pH 2 with dilute aqueous TFA. The reaction was concentrated to remove THF then purified by reverse phase preparative HPLC. The appropriate fractions were combined and concentrated to yield 18.8 mg (73% from
25 compound 43c) of compound 43e for 2 steps.

¹H (CD₃OD) 7.90-6.90 (7H, m), 4.12 (2H, s) [M-H]⁻ 518

Example 44



30

5


3,5-Dichloro-2-fluoro-4-[3-(benzylaminosulfonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylmethylaminopyridine.

The title compound was prepared according to the methodology described for example 43 except that benzyl amine was used in place of 4-fluoroaniline in the step for compound 43b.

^1H (CD_3OD) 7.21-7.17 (6H, m), 7.01 (1H, dd 2.75Hz, 9.07Hz), 6.86 (1H, d 9.34Hz), 4.12 (1H, s), 4.09 (1H, s) $[\text{M}-\text{H}]^-$ 514

15

Example 45




3,5-Dichloro-2-fluoro-4-[3-(isobutylaminosulfonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylmethylaminopyridine.

The title compound was prepared according to the methodology described for example 43 except that isobutyl amine was used in place of 4-fluoroaniline in the step for compound 43b.

^1H (CD_3OD) 7.18 (1H, d 3.30Hz), 7.09 (1H, dd 3.30Hz, 8.80Hz), 6.97 (1H, d 9.34Hz), 4.12 (2H, s), 2.66 (2H, d 6.60Hz), 1.69-1.65 (1H, m), 0.85 (6H, d 6.60Hz) $[\text{M}-\text{H}]^-$ 480

Example 46



5

3,5-Dichloro-2-fluoro-4-[3-(p-tolylsulfonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylmethylaminopyridine.

10

Compound 46a: 3,5-Dichloro-2,6-difluoro-4[3-(p-tolylsulfonyl)-4-hydroxyphenoxy]pyridine

3,5-Dichloro-2,6-difluoro-4-(4-methoxyphenoxy)pyridine
 15 (0.3 g, 1 mmol), tosylchloride (0.2 g, 1 mmol) and aluminum chloride (0.29 g, 2.1 mmol) were heated at 70°C for 14 hrs in 15 ml of dichloroethane. The reaction mixture was diluted with 50ml additional dichloroethane, cooled to 0°C and quenched by the addition of 1 ml of water. After
 20 stirring for 5 minutes, the organic layer was separated, washed with brine, dried (Na₂SO₄) and concentrated. The crude material was purified by silica chromatography to give a 47% yield of compound 46a.

25 ¹H (CDCl₃) 8.90 (1H, s), 7.72 (2H, d 8.14Hz), 7.27 (2H, d 8.24Hz), 7.09 (1H, d 3.29 Hz), 6.98-6.91 (2H, m), 2.36 (3H, s)

Compound 46b: 3,5-Dichloro-2-fluoro-4-[3-(p-tolylsulfonyl)-4-hydroxyphenoxy]-6-methoxycarbonylaminomethylpyridine
 30

5 Compound 46b was prepared according to the method described for compound 43c.

Compound 46c: 3,5-Dichloro-2-fluoro-4-[3-(p-tolylsulfonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylaminomethylpyridine


10

 Compound 46c was prepared according to the methodology described for compound 43e.

¹H (CD₃OD) 7.81 (2H, d 7.91Hz), 7.41 (1H, d 3.08Hz), 7.35 (2H, d 7.91Hz), 7.07 (1H, dd 3.08, 8.29) 4.12 (2H, s), 2.41 (3H, s)

15

Example 47



3,5-Dichloro-2-fluoro-4-[3-(p-fluorobenzenesulfonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylmethylaminopyridine.

25 Compound 47a: 2-(4-Fluorobenzenesulfonyl)-benzene-1,4-diol

 To a solution (50 ml THF) of 4-Fluorobenzenesulfonyl chloride (2 g) was added sodiumborohydride (1.9 g) and the reaction was stirred for 1 hour. The reaction was quenched with 5 ml of water and after stirring for 1 hour was concentrated. Ten ml of 6N HCl was added dropwise and 4-

30

5 fluorobenzenesulfinic acid was extracted with ethyl acetate. The ethyl acetate solution was dried with Na₂SO₄, filtered and concentrated. The resulting residue was dissolved in 5 ml of water and was added dropwise to a methylene chloride solution of 1,4-benzoquinone. The
10 reaction mixture was stirred over night. Compound 47a was filtered and dried to yeild 1.8 g (72%).

Compound 47b: 3,5 Dichloro-2,6-difluoro-4-[3-(p-fluoro-sulfonyl)-4-hydroxyphenoxy]pyridine

15

2,4,6-trifluoro-3,5-dichloropyridine (20.1 mg), 2-(4-fluorobenzenesulfonyl)-benzene-1,4-diol (26.8 mg) and triethylamine (5 µl) were stirred in 1 ml of dimethylformamide overnight. The reaction mixture was
20 concentrated and the crude product purified on a preparative silica gel plate to yield 14 mg of compound 47b.

Compound 47c: 3,5 Dichloro-2,6-difluoro-4-[3-(p-fluoro-sulfonyl)-4-hydroxyphenoxy]-6-methoxycarbonylaminomethyl
25 pyridine

Compound 47c was prepared according to the procedure described for compound 43c.


30

Compound 47d: 3,5-Dichloro-2-fluoro-4-[3-(p-fluorobenzene-sulfonyl)-4-hydroxyphenoxy]-6-hydroxycarbonylaminomethyl pyridine

5 Compound 47d was prepared according to the procedure described for compound 43e.

^1H (CD_3OD) 8.04-8.00 (2H, m), 7.47 (1H, d 3.30Hz), 7.32-7.27 (2H, m), 7.09 (1H, dd 3.30Hz, 9.07 Hz), 6.86 (1H, d 8.80Hz),
10 4.13 (2H, s) (M-H) $^-$ 503

Example 48




15

3,5-Dichloro-2-fluoro-4-(3-methanesulfonyl-4-hydroxyphenoxy)-6-hydroxycarbonylmethylaminopyridine.

The title compound was prepared according to the
20 procedures described for example 47 except that 2-methylsulfonyl-benzene-1,4-diol was prepared from Na methanesulfinat and 1,4-benzoquinone.

^1H (CD_3OD) 7.30 (1H, d 3.30Hz), 7.13 (1H, dd 3.30Hz, 8.80
25 Hz), 7.00 (1H, d 9.35Hz), 4.09 (2H, s), 3.25 (3H, s)

Example 49




30

3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenylamino)-6-hydroxycarbonylmethylaminopyridine.

5

Compound 49a: 3-isopropyl-4-methoxyaniline




10 To a solution of 2-isopropylanisole (0.4 g, 2.66 mmol) in CH₂Cl₂ (13 mL) was added bis-(2,2,2-trichloroethyl)azo-dicarboxylate (2.3 g, 6.04 mmol) and zinc chloride (3 mL, 1.0 M solution in Et₂O, 3.0 mmol). The mixture was left to stir overnight (ca. 18h) at ambient room temperature under
15 N₂. A 25% aqueous ammonium acetate solution (15 mL) was added to quench the reaction. The product was extracted with EtOAc (50 mL). The EtOAc extract was washed with brine (50 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The thick yellow oil crude product was purified by
20 chromatography using the ISCO Combiflash SQ16x system (0 to 50% EtOAc in hexane, 15 min gradient, 35 g Redisep silica gel column) to afford 1.75 g of material which was a mixture of two products. The mixture was dissolved in glacial acetic acid (10 mL). Zinc dust (1 g) was added and
25 the reaction mixture was left to stir overnight (ca. 15 h) under N₂ at ambient room temperature. The reaction was quenched by adding 3 N HCl to dissolve the remaining zinc dust. Water (50 mL) and 50% aqueous NaOH was added to make the mixture basic (ca. pH 10). The product was extracted
30 with EtOAc (100 mL). The EtOAc extract was washed with brine (50 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The crude product was purified by chromatography using the ISCO Combiflash SQ16x system (0 to 50% EtOAc in

5 hexane, 15 min gradient, 35 g Redisep silica gel column) to afford 0.343 g (78%, 2 steps) of compound 49a as a purified orange oil.

^1H NMR (500 MHz, CDCl_3 , δ) 6.68 (d, 1H, $J = 8.8$ Hz), 6.595 (d, 1H, $J = 2.8$ Hz), 6.495 (dd, 1H, $J = 8.2, 2.7$ Hz), 3.75 (s, 3H), 3.29 (broad s, 2H), 3.25 (m, 1H), 1.17 (d, 6H, $J = 7.2$ Hz) MS-ESI $[\text{M}+\text{H}]^+ = 166.2$

Compound 49b: 3,5-dichloro-2,6-difluoro-4-(3-isopropyl-4-methoxyphenylamino)pyridine



To a stirring slurry of 4-amino-2-isopropylanisole (0.150 g, 0.908 mmol) and K_2CO_3 (0.150g, 1.085 mmol) in DMF (3 mL) was added a solution of 3,5 dichloro-2,4,6-trifluoropyridine (0.185 g, 0.916 mmol) in DMF (1.5 mL). The mixture was stirred at ambient room temperature for 2 h. The mixture was partitioned between EtOAc (50 mL) and H_2O (25 mL). The EtOAc extract was washed with brine (25 mL), dried (Na_2SO_4), filtered and concentrated in vacuo. The crude product was purified by chromatography using the ISCO Combiflash SQ16x system (0 to 15% EtOAc in hexane, 15 min gradient, 35 g Redisep silica gel column) to afford 0.279 g (88%) of compound 49b as a purified white solid.

30


^1H NMR (500 MHz, CDCl_3 , δ) 6.92 (d, 1H, $J = 2.2$ Hz), 6.875 (dd, 1H, $J = 8.2, 2.7$ Hz), 6.80 (broad s, 1H), 6.78 (d, 1H,

5 J = 8.8 Hz), 3.84 (s, 3H), 3.31 (m, 1H), 1.175 (d, 6H, J = 7.1 Hz)

MS-ESI [M-H]⁻ = 345.1, 347.1, 348.1 (100:64:10)

Compound 49c: 3,5-dichloro-2-fluoro-4-(3-isopropyl-4-methoxyphenylamino)-6-methoxycarbonylmethylaminopyridine

10



To a solution of compound 49b (0.150 g, 0.432 mmol) and glycine methyl ester hydrochloride (0.160 g, 1.274 mmol) in DMF (4 mL) was added N,N-diisopropylethylamine (0.35 mL, 0.26 g, 2.012 mmol). The mixture was heated to 70°C and maintained at this temperature overnight (ca. 15 h) under N₂. The mixture was cooled down to room temperature and then taken up in EtOAc (50 mL) and H₂O (25 mL). The EtOAc extract was washed with brine (25 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The crude product was purified by chromatography using the ISCO Combiflash SQ16x system (0 to 50% EtOAc in hexane, 15 min gradient, 35 g Redisep silica gel column) to afford 0.065 g of compound 49c (48036-110B) as a white solid.

15

20


25

¹H NMR (500 MHz, CDCl₃, δ) 6.865 (d, 1H, J = 2.2 Hz), 6.785 (dd, 1H, J = 8.8, 2.2 Hz), 6.75 (d, 1H, J = 8.8 Hz), 6.36 (broad s, 1H), 5.49 (t, 1H, J = 5 Hz), 4.19 (d, 2H, J = 5.5 Hz), 3.82 (s, 3H), 3.78 (s, 3H), 3.29 (m, 1H), 1.175 (d, 6H, J = 7.2 Hz)

30

MS-ESI [M-H]⁻ = 414.2, 416.2, 418.2 (100:64:10)


- 5 Compound 49d: 3,5-dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenylamino)-6-hydroxycarbonylmethylaminopyridine



- 10 To a solution of compound 49c (55 mg, 0.132 mmol) in CH_2Cl_2 (3 mL) cooled with an ice- H_2O bath was added boron tribromide (1.3 mL, 1.0 M solution in CH_2Cl_2 , 1.3 mmol). The temperature was allowed to warm up to room temperature. After 2 h, the mixture was poured into a flask containing
15 ice-water (25 mL) and stirred for 10 min. The product was extracted with EtOAc (25 mL). The EtOAc extract was washed with brine (25 mL), dried (Na_2SO_4), filtered and concentrated in vacuo. The crude product was purified by prep HPLC to afford 37.6 mg (73%) of title compound as an
20 orange solid.


- ^1H NMR (500 MHz, CD_3OD , δ) 6.80 (d, 1H, $J = 2.2$ Hz), 6.64 (s, 1H), 6.635 (d, 1H, $J = 2.2$ Hz), 2.06 (s, 2H), 3.24 (m, 1H), 1.17 (d, 6H, $J = 6.6$ Hz)
25 MS-ESI $[\text{M}-\text{H}]^- = 386.1, 388.1, 390.1$ (100:64:10)

5

Example 50


10 **3,5-Dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenylthio)-6-hydroxycarbonylmethylaminopyridine**

Compound 50a: 4-chlorosulfonyl-2-isopropylanisole



To a solution of 2-isopropylanisole (0.40 g, 2.66
15 mmol) in CH₂Cl₂ (9 mL) cooled with an ice water bath was
added slowly chlorosulfonic acid (4 mL). After 1.5 h of
cooling, the mixture was poured into a flask containing ice
(25 g). The product was extracted with CH₂Cl₂ (50 mL). The
organic extract was washed with brine (25 mL), dried
20 (Na₂SO₄), filtered and concentrated in vacuo to afford 0.62
g of grayish oil as crude product. The crude product was
purified by chromatography using the ISCO Combiflash SQ16x
system (0 to 20% EtOAc in hexane, 20 min gradient, 35 g
Redisep silica gel column) to give 0.56 g (84%) of compound
25 50a as a clear oil.


¹H NMR (500 MHz, CDCl₃, δ) 7.87 (dd, 1H, J = 8.8 Hz, 2.2 Hz),
7.82 (d, 1H, J = 2.8 Hz), 6.96 (d, 1H, J = 8.8 Hz), 3.94 (s,
3H), 3.33 (m, 1H), 1.235 (d, 6H, J = 6.6 Hz)
30 MS-DCI⁺ [M-Cl]⁺ = 212.8 (100%)

5 Compound 50b: 4-thio-2-isopropylanisole

A mixture of 4-chlorosulfonyl-2-isopropylanisole (0.30
10 g, 1.21 mmol), zinc dust (0.5 g) in 25% H₂SO₄ (15 ml) was
heated to 110°C and maintained at this temperature for 4 h.
The mixture was cooled down to RT and the product was
extracted with EtOAc (50 mL). The EtOAc extract was washed
with brine (25 mL), dried (Na₂SO₄), filtered and
15 concentrated and dried in vacuo to give 0.18 g (82%) of
compound 50b.

¹H NMR (500 MHz, CDCl₃, δ) 7.165 (d, 1H, J = 2.2 Hz), 7.135
(dd, 1H, J = 8.2 Hz, 2.2 Hz), 6.72 (d, 1H, J = 8.8 Hz), 3.79
20 (s, 3H), 3.25 (m, 1H), 1.17 5 (d, 6H, J = 6.6 Hz)

Compound 50c: 3,5-dichloro-2,6-difluoro-4-(3-isopropyl-4-methoxyphenylthio) pyridine




25 To the crude 4-thio-2-isopropylanisole (0.14 g, 0.77
mmol) in DMF (3 mL) was added potassium carbonate (0.17 g,
1.23 mmol) and a solution of 3,5-dichloro-2,4,6-
trifluoropyridine (0.14 g, 0.69 mmol) in DMF (1 mL). After
2h, the mixture was partitioned between EtOAc (50 mL) and
30 H₂O (25 mL). The EtOAc extract was washed with brine (25

5 mL), dried (Na_2SO_4), filtered and concentrated in vacuo. The crude product was purified by chromatography (50 g silica gel, 2% EtOAc in hexane) to afford 0.18 g (64%) of compound 50c.

10 ^1H NMR (500 MHz, CDCl_3 , δ) 7.29 (d, 1H, $J = 2.2$ Hz), 7.135 (dd, 1H, $J = 8.5$ Hz, 2.2 Hz), 6.76 (d, 1H, $J = 8.8$ Hz), 3.82 (s, 3H), 3.26 (m, 1H), 1.16 (d, 6H, $J = 6.6$ Hz)

Compound 50d: 3,5-dichloro-2-fluoro-4-(3-isopropyl-4-methoxyphenylthio)-6-methoxycarbonylmethylaminopyridine
15




To a solution of compound 50c (0.17 g, 0.47 mmol) and
20 glycine methyl ester hydrochloride (0.12 g, 0.95 mmol) in
N, N-dimethylacetamide (5 mL) was added N,N-
diisopropylethyl-amine (0.35 mL, 0.26g, 2.01 mmol). The
mixture was heated to 70°C and maintained at this
temperature for 3 h. The mixture was cooled to RT and
25 partitioned between EtOAc (50 ml) and H_2O (25 mL). The
EtOAc extract was washed with 1N HCl (25 mL) and brine (25
mL) and then dried (Na_2SO_4), filtered and concentrated in
vacuo. The crude product was purified by chromatography
(50 g silica gel, 15% EtOAc in hexane) to afford 0.15 g
30 (72%) of compound 50d as a white solid.

5 ^1H NMR (400 MHz, CDCl_3 , δ) 7.29 (d, 1H, $J = 2.6$ Hz), 7.15 (dd, 1H, $J = 8.6$ Hz, 2.4 Hz), 6.73 (d, 1H, $J = 8.4$ Hz), 5.71 (t, 1H, $J = 4.8$ Hz), 4.17 (d, 2H, $J = 5.3$ Hz), 3.79 (s, 3H), 3.78 (s, 3H), 3.24 (m, 1H), 1.16 (d, 6H, $J = 7.1$ Hz)
MS-ESI $^-$ $[\text{M}-\text{H}]^- = 431, 433, 435$ (100:64:10)

10

Compound 50e: 3,5-dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenylthio)-6-hydroxycarbonylmethylaminopyridine




15

To a solution of 48036-163 (65 mg, 0.15 mmol) in CH_2Cl_2 (3 mL) cooled with an ice water bath was added boron tribromide (1.0 mL, 1.0 M solution in CH_2Cl_2 , 1.0 mmol). The temperature was allowed to warm up to room temperature.
20 After 2 h, the mixture was poured into a flask containing ice-water (25 mL) and stirred for 10 min. The product was extracted with EtOAc (50 mL). The EtOAc extract was washed with brine (25 mL), dried (Na_2SO_4), filtered and concentrated in vacuo. The crude product was purified by
25 prep HPLC to afford 29 mg (48%) of the title compound as a white solid.

^1H NMR (400 MHz, CD_3OD , δ) 7.20 (d, 1H, $J = 2.7$ Hz), 6.995 (dd, 1H, $J = 8.4$ Hz, 2.7 Hz), 6.68 (d, 1H, $J = 8.4$ Hz), 4.07 (s, 2H), 3.21 (m, 1H), 1.155 (d, 6H, $J = 7.0$ Hz)
30 MS-ESI $^-$ $[\text{M}-\text{H}]^- = 403, 405, 407$ (100:64:10)

5

Example 51

10 **[3,5-Dichloro-6-fluoro-4-(4-hydroxy-3-isopropyl-benzene-sulfinyl)pyridin-2-ylamino]-acetic acid**


To a solution of 3,5-dichloro-2-fluoro-4-(3-isopropyl-4-hydroxyphenylthio)-6-hydroxycarbonylmethylaminopyridine (25 mg, 0.06 mmol) in CH₂Cl₂ (1.5 mL) was added 3-chloroperoxy-benzoic acid (11 mg). The mixture was left to stir overnight (ca. 15h) at ambient room temperature. The product was extracted with EtOAc (25 mL). The organic extract was washed with brine (25 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The isolated crude product was purified by preparative HPLC (from 50% B to 100% B for 10 min, Solvent A = 90% H₂O-10% MeOH-0.1% TFA Solvent B = 10% MeOH-90% H₂O-0.1% TFA, at 20 mL/min using column YMC ODS S5 20 x 100 mm) to afford 16.5 mg (64%) of title compound as a white solid.

25

¹H NMR (400 MHz, CD₃OD, δ) 7.70 (d, 1H, J = 2.2 Hz), 7.435 (dd, 1H, J = 8.8 Hz, 2.2 Hz), 6.89 (d, 1H, J = 8.4 Hz), 4.08 (s, 2H), 3.71 (s, 3H), 3.32-3.37 (m, 1H), 1.21, 1.20 (2d, 6H, J = 7.0 Hz)

30 MS-ESI⁻ [M-H]⁻ = 419, 421, 423 (100:64:10)

Example 52



5


[3,5-Dichloro-6-fluoro-4-(4-hydroxy-3-isopropyl-benzene-sulfanyl)pyridin-2-ylamino]acetic acid methyl ester

10 To a solution of [3,5-dichloro-6-fluoro-4-(3-isopropyl-4-methoxy-phenylsulfanyl)-pyridin-2-ylamino]-acetic acid methyl ester (600 mg, 1.38 mmol) in CH_2Cl_2 (14 mL) cooled with an ice water bath was added boron tribromide (0.65 mL, 1.72 g, 6.87 mmol). The temperature
15 was allowed to warm up to RT. After 2 h, the mixture was slowly poured into a flask containing EtOAc (100 mL) and saturated aqueous NaHCO_3 solution (75 mL). The EtOAc extract was washed with brine (50 mL), dried (Na_2SO_4), filtered and concentrated in vacuo. The crude product was
20 refluxed in methanolic HCl (30 mL) for 2 h. The temperature was cooled to room temperature and then concentrated in vacuo. The crude product was purified by chromatography using the ISCO Combiflash SQ16X system (35 g Redisep silica gel column, 0 to 50% EtOAc in hexane for 30
25 min at 30 mL/min) to afford 517.4 mg (89%) of the title compound as a yellowish thick oil.

^1H NMR (500 MHz, CDCl_3 , δ) 7.30 (d, 1H, $J = 2.2$ Hz), 7.045 (dd, 1H, $J = 8.2$ Hz, 2.2 Hz), 6.65 (d, 1H, $J = 8.8$ Hz), 5.71 (t, 1H, $J = 5.0$ Hz), 4.86 (s, 1H), 4.175 (d, 2H, $J = 5.0$ Hz), 3.78 (s, 3H), 3.18-3.11 (m, 1H), 1.21 (d, 6H, $J = 7.2$ Hz)

MS-ESI $^-$ $[\text{M}-\text{H}]^- = 417, 419, 421$ (100:64:10)

5

Example 53

10 **[3,5-Dichloro-6-fluoro-4-(4-hydroxy-3-isopropyl-benzenesulfonyl)pyridin-2-ylamino]acetic acid methyl ester**


To a solution of [3,5-dichloro-6-fluoro-4-(4-hydroxy-3-isopropyl-benzenesulfonyl)pyridin-2-ylamino]acetic acid methyl ester (title compound of example 52) (175 mg, 0.42 mmol) in CH₂Cl₂ (8 mL) was added 3-chloroperoxybenzoic acid (300 mg). The mixture was left to stir overnight (ca. 15h) at ambient room temperature. The mixture was poured into a flask containing saturated aqueous NaHCO₃ (50 mL). The product was extracted with CH₂Cl₂ (100 mL). The organic extract was washed with brine (50 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The crude product was purified by chromatography using the ISCO Combiflash SQ16X system (35 g Redisep silica gel column, 0 to 75% EtOAc in hexane for 20 min at 30 mL/min) to afford 167.3 mg (89%) of desired product as a white solid which was 92% pure by analytical HPLC. The product isolated was further purified by preparative HPLC (from 50% B to 100% B for 10 min, Solvent A = 90% H₂O-10% MeOH-0.1% TFA Solvent B = 10% MeOH-90% H₂O-0.1% TFA, at 20 mL/min using column YMC ODS S5 20 x 100 mm) to afford 90 mg of the title compound as a white solid.

5

^1H NMR (500 MHz, CD_3OD , δ) 7.88 (d, 1H, $J = 2.8$ Hz), 7.73 (dd, 1H, $J = 8.8$ Hz, 2.2 Hz), 6.65 (d, 1H, $J = 8.8$ Hz), 4.11 (s, 2H), 3.71 (s, 3H), 3.33–3.28 (m, 1H), 1.22 (d, 6H, $J = 7.1$ Hz)

10 MS-ESI $^-$ $[\text{M}-\text{H}]^- = 449, 451, 453$ (100:64:10)

Example 54



15

[3,5-Dichloro-6-fluoro-4-(4-hydroxy-3-isopropyl-benzene-sulfonyl)pyridin-2-ylamino]acetic acid

To a solution of the title compound of example 53 (90 mg, 0.20 mmol) in THF (2 mL) was added 1N LiOH aqueous solution (0.6 mL). After an hour, the mixture was acidified with 1N HCl and the product was extracted with EtOAc (50 mL). The organic extract was washed with brine (20 mL), dried (Na_2SO_4), filtered and concentrated and dried in vacuo to afford 77.4 mg (89%) of the title compound as a white solid.


25

^1H NMR (500 MHz, CD_3OD , δ) 7.88 (d, 1H, $J = 2.2$ Hz), 7.73 (dd, 1H, $J = 8.8$ Hz, 2.2 Hz), 6.91 (d, 1H, $J = 8.2$ Hz), 4.07 (s, 2H), 3.71 (s, 3H), 3.32–3.27 (m, 1H), 1.22 (d, 6H, $J = 7.1$ Hz)

30


MS-ESI $^-$ $[\text{M}-\text{H}]^- = 435, 437, 439$ (100:64:10)

5

Example 55

10 **{3,5,dichloro-4-[cyano-(3-isopropyl-4-methoxy-phenyl)-methyl]-6-fluoro-pyridin-2-ylamino}-acetic acid methyl ester**

Compound 55a: (3-Isopropyl-4-methoxyphenyl)methanol




15 To a solution of 3-isopropyl-4-methoxy-benzaldehyde (1.5 g, 8.42 mmol) in anhydrous THF (17 mL) cooled to -78°C with a dry ice-acetone bath was added diisobutylaluminum hydride (34 mL, 1.0 M solution in THF, 34 mmol). After 1.5 h of cooling, 1N HCl (30 mL) was slowly added to the
20 mixture. After the addition, the cooling bath was removed and the mixture left to stir at RT (ca. 15 min). The product was extracted with EtOAc (100 mL). The EtOAc extract was washed with brine (50 mL), dried (Na₂SO₄), filtered, and concentrated in vacuo to give 1.405 g of
25 colorless oil as crude product. The crude product was purified by chromatography using the ISCO Combiflash SQ16X system (35 g Redisep silica gel column, 0 to 40% EtOAc in hexane for 30 min at 30 mL/min) to afford 1.272 g (84%) of compound 55 as a colorless oil.

30


5 ^1H NMR (500 MHz, CDCl_3 , δ) 7.21 (d, 1H, $J = 2.2$ Hz), 7.16 (dd, 1H, $J = 8.3, 2.2$ Hz), 6.825 (d, 1H, $J = 8.3$ Hz), 4.61 (d, 2H, $J = 6.1$ Hz), 3.82 (s, 3H), 3.31 (heptet, 1H, 6.6 Hz), 1.50 (t, 1H, $J = 5.8$ Hz), 1.205 (d, 6H, $J = 7.1$ Hz)

10 Compound 55b: 4-Bromomethyl-2-isopropyl-1-methoxybenzene



To a solution of (3-isopropyl-4-methoxy-phenyl)-methanol (0.400g, 2.219 mmol) in CH_2Cl_2 (4.5 mL) was added
15 phosphorus tribromide (2.3 mL, 1.0 M solution in CH_2Cl_2 , 2.300 mmol). After 2h, H_2O (25 mL) was added to quench the mixture. The product was extracted with CH_2Cl_2 (50 mL). The organic extract was washed succesively with saturated NaHCO_3 solution (2 x 25 mL) and brine (25 mL). The organic
20 extract was dried (Na_2SO_4), filtered, concentrated and dried in vacuo to afford 0.5294 mg (98% crude yield) of compound 55b as a colorless oil.

^1H NMR (500 MHz, CDCl_3 , δ) 7.215 (d, 1H, $J = 2.2$ Hz), 7.195
25 (dd, 1H, $J = 8.2, 2.2$ Hz), 6.785 (d, 1H, $J = 8.3$ Hz), 4.51 (s, 2H), 3.82 (s, 3H), 3.28 (heptet, 1H, 7.1 Hz), 1.20 (d, 6H, $J = 6.6$ Hz)


5 Compound 55c: (3-Isopropyl-4-methoxyphenyl)acetonitrile:

Sodium cyanide (0.500 g, 10.202 mmol) in DMSO (4 mL) was heated to 100°C. After a few minutes of heating, most
10 of the sodium cyanide was dissolved. A solution of the crude 4-bromoethyl-2-isopropyl-1-methoxy-benzene (0.500 g, 2.065 mmol) in DMSO (1.5 mL) was added to the sodium cyanide solution. After an hour of heating, the mixture was cooled to RT and the product partitioned between EtOAc
15 (100 mL) and H₂O (50 mL). The EtOAc extract was washed with brine, dried (Na₂SO₄), filtered and concentrated in vacuo. The crude product was purified by chromatography using the ISCO Combiflash SQ16X system (35 g Redisep silica gel column, 0 to 20% EtOAc in hexane for 20 min at 30 mL/min)
20 to afford 0.326 g (84%) of compound 55c as a colorless oil.

¹H NMR (500 MHz, CDCl₃, δ) 7.11 (dd, 1H, J = 6.5, 2.7 Hz), 7.10 (s, 1H), 6.815 (dd, 1H, J = 6.6, 2.8 Hz), 3.82 (s, 3H), 3.67 (s, 2H), 3.29 (heptet, 1H, 6.6 Hz), 1.195 (d, 6H, J =
25 6.6 Hz)
MS-DCI : [M-H]⁻ 188.2

Compound 55d: (3,5-dichloro-2,6-difluoro-pyridin-4-yl)-(3-isopropyl-4-methoxyphenyl)acetonitrile

30



5

To a stirring slurry of sodium hydride (30 mg, 60% dispersion, 0.75 mmol) in DMF (1 mL) was added a solution of (3-isopropyl-4-methoxy-phenyl)-acetonitrile (70 mg, 0.37 mmol) in DMF (1 mL). The mixture was stirred for ca. 10 min, then a solution of 3,5-dichloro-2,4,6-trifluoropyridine in DMF (1.5 mL) was added. After 2h, the mixture was quenched with H₂O (10 mL) and the product was extracted with EtOAc (50 mL). The EtOAc extract was washed with brine, dried (Na₂SO₄), filtered, and concentrated in vacuo. The crude product was purified by preparative HPLC (from 50% B to 100% B for 10 min, Solvent A = 90% H₂O-10% MeOH-0.1% TFA Solvent B = 10% MeOH-90% H₂O-0.1% TFA, at 20 mL/min using column YMC ODS S5 20 x 100 mm) to afford 59.3 mg (43%) of compound 55d as a white solid.


20

¹H NMR (500 MHz, CDCl₃, δ) 7.25 (d, 1H, J = 2.7 Hz), 7.095 (dd, 1H, J = 7.7 2.8 Hz), 6.80 (d, 1H, J = 8.8 Hz), 6.11 (s, 1H), 3.81 (s, 3H), 3.27 (heptet, 1H, 7.1 Hz), 1.185, 1.16 (2d, 6H, J = 6.6 H, 7.2 Hz)

25 MS-ESI : [M-H]⁻ 369, 371, 373 (100:64:10)

Compound 55e: {3,5,dichloro-4-[cyano-(3-isopropyl-4-methoxy-phenyl)-methyl]-6-fluoropyridin-2-ylamino}acetic acid methyl ester


30



20 ¹H NMR (500 MHz, CDCl₃, δ) 7.265 (d, 1H, J = 2.7 Hz), 7.095
(dd, 1H, J = 7.7, 2.7 Hz), 6.78 (d, 1H, J = 8.2 Hz), 6.02
(s, 1H), 5.79 (t, 1H, J = 5.0 Hz), 4.185 (d, 2H, J = 5.5
Hz), 3.80 (s, 3H), 3.79 (s, 3H), 3.27 (heptet, 1H, 6.6 Hz),
1.19, 1.165 (2d, 6H, J = 6.6, 6.6 Hz).

25 MS ESI⁻ [M-H]⁻ : 438, 440, 442 (100:64:10)

{3,5,dichloro-4-[cyano-(4-hydroxy-3-sopropylphenyl)-methyl]-6-fluoropyridin-2-ylamino}acetic acid



5 To a solution of {3,5-dichloro-4-[cyano-(3-isopropyl-4-methoxy-phenyl)-methyl]-6-fluoro-pyridin-2-ylamino}-acetic acid methyl ester (35 mg, 0.08 mmol) in CH₂Cl₂ (2 mL) cooled with an ice-water bath was added boron tribromide (1.0 ml, 1.0 M solution in CH₂Cl₂, 1.0 mmol). The
10 temperature was allowed to warm up to RT. After 2 h, the mixture was poured into a flask containing ice water (25 mL). The product was extracted with EtOAc (50 mL). The organic extract was washed with brine (25 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The crude
15 product isolated was purified by preparative HPLC (from 50% B to 100% B for 10 min, Solvent A = 90% H₂O-10% MeOH-0.1% TFA Solvent B = 10% MeOH-90% H₂O-0.1% TFA, at 20 mL/min using column YMC ODS S5 20 x 100 mm) to afford 24.2 mg (74%) of the title compound as a white solid.


20

¹H NMR (400 MHz, CD₃OD, δ) 7.205 (d, 1H, J = 2.2 Hz), 6.925 (dd, 1H, J = 8.8 Hz, 2.2 Hz), 6.72 (d, 1H, J = 8.2 Hz), 6.19 (s, 1H), 4.10 (s, 2H), 3.25 (heptet, 1H, J = 6.6 Hz), 1.185, 1.165 (2d, 6H, J = 7.2, 6.6 Hz)

25 MS-ESI⁻ [M-H]⁻ = 410, 412, 414 (100:64:10)

Example 57

30 **[3,5-Dichloro-6-fluoro-4-(4-hydroxy-3-isopropyl-benzoyl)-pyridin-2-ylamino]-acetic acid**



5

To a solution of crude {3,5,dichloro-4-[cyano-(4-hydroxy-3-isopropyl-phenyl)-methyl]-6-fluoro-pyridin-2-ylamino}-acetic acid (24 mg, 0.058 mmol) in DMSO (2 mL) was added K₂CO₃ (28 mg, 0.202 mmol) in H₂O (2 mL). The mixture was left to stir overnight at ambient room temperature in an open flask. The mixture was acidified with 1N HCl and the product was partitioned between EtOAc (50 mL) and H₂O (25 mL). The organic extract was washed with brine (25 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The crude product was purified by preparative HPLC (from 50% B to 100% B for 10 min, Solvent A = 90% H₂O-10% MeOH-0.1% TFA Solvent B = 10% MeOH-90% H₂O-0.1% TFA, at 20 mL/min using column YMC ODS S5 20 x 100 mm) to afford 7.95 mg (34% for 2 steps) of the title compound.

20









¹H NMR (400 MHz, CD₃OD, δ) 7.77 (d, 1H, J = 1.1 Hz), 7.435 (dd, 1H, J = 8.8 Hz, 2.2 Hz), 6.82 (d, 1H, J = 8.3 Hz), 4.14 (s, 1H), 4.12 (s, 1H). 3.30-3.27 (m, 1H), 1.225 (d, 6H, J = 6.6 Hz)









25 MS-ESI⁻ [M-H]⁻ = 399, 401, 403 (100:64:10)

The following examples were prepared using the procedures or a variation thereof, as described in the aforementioned examples and schemes.









30









5

Example #	Structure	molecular weight	$[M+H]^+$	$[M-H]^-$
58		346.19		343.88
59		478.37		475.74
60		347.13		344.85
61		374.25	374	372
62		437.26		435
63		451.29		449
64		437.26		435
65		453.24	455	


66		331.18	328.9
67		446.26	444
68		439.21	436.9
69		417.22	415
70		386.23	385.9
71		425.18	422.8
72		356.3	355
73		374.2	372.1

5

74		425.29	426	424
75		419.28	419	417
76		504.39	505	502
77		456.35	456	
78		387.28		386
79		416.28	416	415
80		389.26	389	387
81		403.28	403	401

82		440.31	441	
83		451.33	451	449
84		404.27	405	403
85		403.24	401	
86		459.35		457
87		546.39	548	
88		573.43		571
89		518.35		516


90



373.3

373

91




385.3

385

383


92



389.3

387


93



389.3

387

94




389.3

389

387







95








389.3


389

387

96		403.3	403	401
97		403.3	403	401
98		403.3	403	401
99		403.3	403	401
100		405.3	405	403
101		417.3	417	415

102		417.3	417	415
103		417.3	417	415
104		419.3		417
105		419.3	419	417
106		431.3	431	


107



433.3

431

108




435.3

435

433

109




436.3

436

434


110



441.4

441

111




449.4

449







447








112














449.4

450


113		465.4	465	
114		467.4	465	
115		474.4	474	472
116		401.3	401	399
117		504.4	504	502
118		526.3	526	524

119		520.35	518
120		551.36	549
121		328.2	328.05
122		348.62	345.9
123		457.7	455
124		492.1	491
125		492.1	491

126		515.3	515
127		465.3	465
128		497.3	497
129		513.8	514
130		445.3	445
131		445.3	455


132		417.3	417
133		433.3	433
134			417
135	 Chiral		485.91
136			432.86

137




494.85

138




488.88

139




432.86

140
















461







141














462.87




148		480.28	478
149		405.67	403.1
150		505.38	503
151		454.26	452
152		403.24	401.3
153		489.24	487
154		491.23	489

155		662.24	661
156		417.3	417.16
157		417.3	417.15
158		431.3	431.16
159		431.3	431.16
160		509.4	509.19

161		Chiral	509.4	509.17
162		Chiral	495.4	495.12
163		Chiral	445.3	445.17
164		Chiral	445.3	445.14
165		Chiral	485.4	485.1

166		513.8	514
167		513.8	514
168		493.4	493.16
169		433.3	433.15
170		485.4	485.17
171		509.4	509.17


172



525.4

525.14


173



502.4

502.19


174



419.2

419.15


175



446.3








446.12

176

















419.2








419.13








177		431.3	431.3	
178		402.26	402.1	400.1
179		416.28	416.21	
180		416.28		414.23
181		472.69		471.6
182		466.3		463.7
183		430.27	430.38	428.34








- 126 -








192		429.26	429	
193		499.8	499.1	
194		439.69	439	
195		437.26	437	435
196		502.13	502	
197		554.39	554	
198		361.16	359	








199		431.34	428.8
200		426.03	424.9
201		468.11	466
202		403.24	401
203		423.23	421
204		375.19	373
205		440.06	438








206		465.31		463
207		430.27	430.18	428.1
208		388.23	388.11	386
209		361.16		358.9
210		417.27		415
211		468.11		466
212		417.27		415

213		465.31	463
214		482.14	481
215		479.34	477
216		403.24	401
217		515.11	513
218		423.66	421
219		442.09	438.88

220		407.66	405.02
221		403.24	401
222		417.27	414.9
223		431.29	429
224		403.24	401
225		401.22	399
226		399.21	396.9


227		439.3	437.11
228		391.19	388.9
229		447.25	445
230		387.24	384.8
231		471.29	468.98
232		455.29	452.98
233		415.28	414

234		446.27		444
235		433.33	433.13	431.1
236				463.01
237		437.26		435
238		462.01		460
239		459.21		457
240		468.11		466

241		465.31	463
242		397.14	395
243		383.11	381
244		389.21	386.9
245		372.76	370.8
246		474.09	472.7
247		505.74	504.8

5 What is claimed is:

1. A compound of the formula



10

wherein

X is selected from the group consisting of oxygen, sulfur, sulfoxide, sulfonyl, $-CR_8R_8'$ and $-NR_8$;

Y is selected from the group consisting of $-NR_8$,
 15 oxygen, $-CH_2-$ and sulfur;

Z is a bond or substituted or unsubstituted C_{1-4} alkyl;

R_1 is selected from the group consisting of halogen, trifluoromethyl, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted aryl, substituted or
 20 unsubstituted heteroaryl, aryloxy, substituted amide, sulfone, sulfonamide and C_{3-7} cycloalkyl, wherein said aryl, heteroaryl or cycloalkyl ring(s) are attached or fused to the aromatic ring;

R_{1a} is selected from the group consisting of hydrogen,
 25 halogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R_2 and R_3 are each independently selected from the group consisting of hydrogen, halogen, unsubstituted or
 30 substituted C_{1-4} alkyl and unsubstituted or substituted C_{3-5} cycloalkyl, wherein at least one of R_2 and R_3 being other than hydrogen;

R_4 is selected from the group consisting of hydrogen, halogen, amino, $O-R_7$ and $S-R_7$;

- 5 R_5 is selected from the group consisting of hydroxyl, carboxylic acid, sulfonic acid and phosphonic acid;
 R_6 is selected from the group consisting of hydrogen, alkyl, alkanoyl and aroyl;
 R_7 is hydrogen or C_{1-4} alkyl;
- 10 R_8 for each occurrence is independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, aryl
- 15 or substituted aryl, arylalkyl or substituted arylalkyl, alkoxy and hydroxyl; and
 R_8' is selected from the group consisting of hydrogen, a bond, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl
- 20 or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, arylalkyl or substituted arylalkyl, alkoxy and hydroxyl, or R_8 and R_8' together form a carbonyl,
 including all prodrug, stereoisomers and
- 25 pharmaceutically acceptable salts thereof.
2. The compound as defined in claim 1 wherein
X is selected from the group consisting of oxygen, sulfur, sulfoxide, sulfonyl, $-CH_2-$ and $-NH-$;
- 30 Y is $-NH-$ or oxygen;
 R_1 is selected from the group consisting of halogen, substituted or unsubstituted C_{1-6} alkyl, substituted aryl, aryloxy, substituted amide, sulfone, sulfonamide and C_{3-7} cycloalkyl, wherein R_1 is attached ortho to the R_6O group;
- 35 R_2 and R_3 are each independently selected from the group consisting of iodo, bromo, chloro and fluoro;
 R_4 is selected from the group consisting of hydrogen, fluoro, chloro, amino, $-OCH_3$ and hydroxyl;

- 5 R_5 is carboxylic acid; and
 R_6 is hydrogen.

3. The compound as defined in claim 1 wherein
 X is selected from the group consisting of carbonyl,
 10 CHR_8 and NR_8 ;

 Y is oxygen or $-NH-$;

R_1 is selected from the group consisting of halogen,
 substituted or unsubstituted C_{1-6} alkyl, substituted aryl,
 substituted amide, sulfone, sulfonamide and C_{3-7} cycloalkyl;


- 15 R_2 and R_3 each independently are selected from the
 group consisting of bromo, chloro and methyl;

R_4 is selected from the group consisting of hydrogen,
 fluoro, chloro, hydroxyl, amino and methoxy;

R_5 is carboxylic acid; and

- 20 R_6 is hydrogen.


4. The compound as defined in claim 1 having the
 structure



5. The compound as defined in claim 4 wherein
 Y is oxygen or $-NH-$;
 R_2 and R_3 are halogen;
 30 R_4 is selected from the group consisting of hydrogen,
 halogen, amino, $-OCH_3$ and hydroxyl; and
 R_{10} is selected from the group consisting of hydrogen,
 halogen and substituted and unsubstituted C_{1-4} alkyl.
 R_{1a} is selected from hydrogen, methyl and ethyl.

5

6. The compound as defined in claim 1 having the structure




10









wherein R_1 is substituted or unsubstituted aryl.

7. The compound as defined in claim 1 having the structure



15




5




10



8. The compound as defined in claim 1 having the structure



- 5 9. The compound as defined in claim 1 having the structure



- 10 10. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.

5 11. The pharmaceutical composition of claim 10
further comprising at least one additional therapeutic agent
selected from the group consisting of other compounds of
formula I, anti-diabetic agents, anti-osteoporosis agents,
anti-obesity agents, growth promoting agents, anti-
10 inflammatory agents, anti-anxiety agents, anti-depressants,
anti-hypertensive agents, cardiac glycosides,
cholesterol/lipid lowering agents, appetite suppressants,
bone resorption inhibitors, thyroid mimetics, anabolic
agents, anti-tumor agents and retinoids.

15

 12. The pharmaceutical composition of claim 11
wherein said additional therapeutic agent is an antidiabetic
agent selected from the group consisting of a biguanide, a
glucosidase inhibitor, a meglitinide, a sulfonylurea, a
20 thiazolidinedione, a PPAR-alpha agonist, a PPAR-gamma
agonist, a PPAR alpha/gamma dual agonist, an SGLT2
inhibitor, a glycogen phosphorylase inhibitor, an aP2
inhibitor, a glucagon-like peptide-1 (GLP-1), a dipeptidyl
peptidase IV inhibitor and insulin.

25

 13. The pharmaceutical composition of claim 11
wherein said additional therapeutic agent is an
antidiabetic agent selected from the group consisting of
metformin, glyburide, glimepiride, glipyrider, glipizide,
30 chlorpropamide, gliclazide, acarbose, miglitol,
troglitazone, pioglitazone, englitazone, darglitazone,
rosiglitazone and insulin

 14. The pharmaceutical composition of claim 11
35 wherein said additional therapeutic agent is an anti-obesity
agent is selected from the group consisting of an aP2
inhibitor, a PPAR gamma antagonist, a PPAR delta agonist, a

5 beta 3 adrenergic agonist, a lipase inhibitor, a serotonin reuptake inhibitor and an anorectic agent.

15 15. The pharmaceutical composition of claim 11 wherein said additional therapeutic agent is a hypolipidemic agent selected from the group consisting of a
10 thiazolidinedione, an MTP inhibitor, a squalene synthetase inhibitor, an HMG CoA reductase inhibitor, a fibric acid derivative, an ACAT inhibitor, a cholesterol absorption inhibitor, an ileal Na⁺/bile cotransporter inhibitor, a bile
15 acid sequestrant and a nicotinic acid or a derivative thereof.

20 16. A method for preventing, inhibiting or treating a disease associated with metabolism dysfunction, or which is dependent on the expression of a T₁ regulated gene, which
20 comprises administering to a mammalian patient in need of treatment a therapeutically effective amount of a compound as defined in claim 1.

25 17. A method for treating or delaying the progression or onset of obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, subclinical hyperthyroidism, non-toxic goiter, reduced bone
30 mass, density or growth, eating disorders, reduced cognitive function, thyroid cancer, glaucoma, cardiac arrhythmia, congestive heart failure or a skin disorder or disease, which comprises administering to mammalian patient
in need of treatment a therapeutically effective amount of a compound as defined in claim 1.

35

18. The method according to claim 17 wherein the skin disorder or disease is dermal atrophy, keloids, stria, cellulite, roughened skin, actinic skin damage, lichen

5 planus, ichthyosis, acne, psoriasis, Dernier's disease, eczema, atopic dermatitis, chloracne, pityriasis or skin scarring.

10 19. The method according to claim 17 further comprising administering, concurrently or sequentially, a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of other compounds of formula I, anti-diabetic agents, anti-osteoporosis agents, anti-obesity agents, growth promoting
15 agents, anti-inflammatory agents, anti-anxiety agents, anti-depressants, anti-hypertensive agents, cardiac glycosides, cholesterol/lipid lowering agents, appetite suppressants, bone resorption inhibitors, thyroid mimetics, anabolic agents, anti-tumor agents and retinoids.

20


20. A method of treating or delaying the progression or onset of a skin disorder or disease which comprises administering to a mammalian patient a therapeutically effective amount of a compound as defined in claim 1 in
25 combination with a retinoid or a vitamin D analog.

21. A method for treating or delaying the progression or onset of obesity which comprises administering to mammalian patient in need of treatment a therapeutically
30 effective amount of a compound as defined in Claim 1.

22. A method according to claim 21 further comprising administering, concurrently or sequentially, a therapeutically effective amount of at least one additional
35 therapeutic agent selected from the group consisting of an anti-obesity agent and an appetite suppressant.

5 23. A method according to claim 22 wherein said anti-obesity agent is selected from the group consisting of aP2 inhibitors, PPAR gamma antagonists, PPAR delta agonists, beta 3 adrenergic agonists, lipase inhibitors, serotonin (and dopamine) reuptake inhibitors, other thyroid receptor
10 beta agents and anorectic agents.

24. A compound of the formula



15

wherein

X is selected from the group consisting of oxygen, sulfur, sulfoxide, sulfonyl, $-CR_8R_8'$ and $-NR_8$;

Y is selected from the group consisting of $-NR_8$,
20 oxygen, $-CH_2-$ and sulfur;

Z is a bond or substituted or unsubstituted C_{1-4} alkyl;

R_1 is selected from the group consisting of halogen, trifluoromethyl, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted aryl, substituted or
25 unsubstituted heteroaryl, aryloxy, substituted amide, sulfone, sulfonamide and C_{3-7} cycloalkyl;

R_{1a} is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted aryl and substituted or unsubstituted
30 heteroaryl;

R_2 and R_3 are each independently selected from the group consisting of hydrogen, halogen, unsubstituted or substituted C_{1-4} alkyl and unsubstituted or substituted C_{3-5} cycloalkyl, wherein at least one of R_2 and R_3 being other
35 than hydrogen;

- 5 R_4 is selected from the group consisting of hydrogen, halogen, amino, $O-R_7$, $S-R_7$, and unsubstituted or substituted C_{1-4} alkyl;
- R_5 is selected from the group consisting of hydroxyl, carboxylic acid, sulfonic acid and phosphonic acid;
- 10 R_6 is selected from the group consisting of hydrogen, alkyl, alkanoyl and aroyl;
- R_7 is hydrogen or C_{1-4} alkyl;
- R_8 for each occurrence is independently selected from the group consisting of hydrogen, alkyl or substituted
- 15 alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, arylalkyl or substituted arylalkyl, alkoxy and hydroxyl; and
- 20 R_8' is selected from the group consisting of hydrogen, a bond, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, arylalkyl or
- 25 substituted arylalkyl, alkoxy and hydroxyl, or R_8 and R_8' together form a carbonyl,
- including all prodrug, stereoisomers and pharmaceutically acceptable salts thereof.
- 30 25. A pharmaceutical composition which functions as a selective agonist of the thyroid hormone receptor-beta comprising a compound as defined in claim 1.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
20 November 2003 (20.11.2003)

PCT

(10) International Publication Number
WO 2003/094845 A3

(51) International Patent Classification⁷: **C07D 213/30**,
213/32, 213/36, 213/55, A61K 31/44

(21) International Application Number:
PCT/US2003/014222

(22) International Filing Date: 7 May 2003 (07.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/378,497 8 May 2002 (08.05.2002) US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZHANG, Minsheng** [US/US]; 31 Schcurman Terracc, Warren, NJ 07059 (US). **HANGELAND, Jon** [US/US]; 234 Louise Drive, Morrisville, PA 19067 (US). **CARINGAL, Yolanda** [US/US]; 307 Fountayne Lane, Lawrenceville, NJ 08648 (US). **FRIENDS, Todd** [US/US]; 12 Chatham Court, Robbinsville, NJ 08691 (US).

(74) Agents: **O'BRIEN, Maureen et al.**; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
4 March 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRIDINE-BASED THYROID RECEPTOR LIGANDS



(57) Abstract: Novel pyridine-based thyroid receptor ligands are provided which have the general formula (I) wherein: X is oxygen (-O-), sulfur (-S-), sulfoxide (-S(O)-), sulfonyl (-SO₂-), CR₈R₈' or NR₈; Y is -NR₈, oxygen (-O-), -CH₂- or sulfur (-S-); Z is a bond or substituted or unsubstituted C₁₋₄ alkyl; and wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or

which are dependent upon the expression of a T₃ regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/14222

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 213/30, 213/32, 213/36, 213/55; A61K 31/44

US CL : 546/22, 290, 304, 329, 339; 514/ 345, 349, 352

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 546/22, 290, 304, 329, 339; 514/ 345, 349, 352

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN.Registry, Caplus, Uspatful,

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6534522 B2 (BIGGE et al) 18 MARCH 2003 (18.03.2003), column 45 line 45	1-25
A	US 6221911 B1 (LAVIN et al) 04 April 2001 (04.04.2001) Column 16 claim 2.	1-25

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

13 November 2003 (13.11.2003)

Date of mailing of the international search report

22 DEC 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Alan Rotman

Telephone No. 703-308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/14222

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US03/14222

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.
Group I, claim(s) 1-25 In part , drawn to compounds, pharmaceuticals and method of treating using these compounds wherein X and Y are both Oxygen.

Group II, claim(s) 1-25 in part , drawn to compounds, pharmaceuticals and method of treating using these compounds wherein X is oxygen and Y is NR8

Group III, claim(s) 1-25 in part , drawn to compounds, pharmaceuticals and method of treating using these compounds wherein X is Oxygen and Y is S or CH2.

Group IV, claim(s) 1-25 in part , drawn to compounds, pharmaceuticals and method of treating using these compounds wherein X is S and Y is O, NR8 , S or CH2.

Group V, claim(s) 1-25 in part , drawn to compounds, pharmaceuticals and method of treating using these compounds wherein X is CR8R8' and Y is O, NR8 , S or CH2

(f) "Markush Practice." The situation involving the so-called "Markush practice" wherein a single claim defines alternatives (chemical or non-chemical) is also governed by Rule 13.2. In this special situation, the requirement of a technical interrelationship and the same or corresponding special technical features as defined in Rule 13.2, shall be considered to be met when the alternatives are of a similar nature.

(i) When the Markush grouping is for alternatives of chemical compounds, they shall be regarded as being of a similar nature where the following criteria are fulfilled:

(A) all alternatives have a common property or activity, **and**

(B)(1) a common structure is present, i.e., a significant structural element is shared by all of the alternatives, or

(B)(2) in cases where the common structure cannot be the unifying criteria, all alternatives belong to a recognized class of chemical compounds in the art to which the invention pertains.

(ii) In paragraph (f)(i)(B)(1), above, the words "significant structural element is shared by all of the alternatives" refer to cases where the compounds share a common chemical structure which occupies a large portion of their structures, or in case the compounds have in common only a small portion of their structures, the commonly shared structure constitutes a structurally distinctive portion in view of the existing prior art. The structural element may be a single component or a combination of individual components linked together. The different X and Y substituents have so many permutations and combinations, they have different bonding and properties , and have achieved a different status in the art . The terms X and Y , are so broad in scope that a prior art reference anticipating the claims with respect to one member under 35 USC 102(b) would not render obvious the same claims under 35 USC 103a with respect to another member.

Also when a preliminary search was done on the core it gave numerous iterations indicating that applicants core is not the applicants contribution over the prior art, and does not constitutes a structurally distinctive portion in view of the existing prior art.

Thus Lack of Unity is proper.